https://trial.medpath.com/news/new-data-on-pst-611-from-pulsesight-therapeutics-sas-shared-at-ever-congress-2024 2024-11-13T17:23:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-data-on-pst-611-from-pulsesight-therapeutics-sas-shared-at-ever-congress-2024 2024-11-13T17:23:28+00:00 weekly 0.7 https://trial.medpath.com/news/koselugo-demonstrates-clinically-meaningful-improvement-in-adults-with-symptomatic 2024-11-13T17:17:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/koselugo-demonstrates-clinically-meaningful-improvement-in-adults-with-symptomatic 2024-11-13T17:17:50+00:00 weekly 0.7 https://trial.medpath.com/news/kezar-struck-again-with-second-fda-hold-clinical-trials-arena 2024-11-13T17:15:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kezar-struck-again-with-second-fda-hold-clinical-trials-arena 2024-11-13T17:15:47+00:00 weekly 0.7 https://trial.medpath.com/news/syndax-s-stock-sinks-by-25-despite-aml-trial-meeting-primary-endpoint 2024-11-13T17:15:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syndax-s-stock-sinks-by-25-despite-aml-trial-meeting-primary-endpoint 2024-11-13T17:15:45+00:00 weekly 0.7 https://trial.medpath.com/news/momelotinib-wins-canadian-approval-for-myelofibrosis-with-anemia-onclive 2024-11-13T17:08:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/momelotinib-wins-canadian-approval-for-myelofibrosis-with-anemia-onclive 2024-11-13T17:08:39+00:00 weekly 0.7 https://trial.medpath.com/news/ge-healthcare-receives-fda-clearance-for-head-only-signa-magnus-3-0t-mri-system 2024-11-13T17:06:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ge-healthcare-receives-fda-clearance-for-head-only-signa-magnus-3-0t-mri-system 2024-11-13T17:06:45+00:00 weekly 0.7 https://trial.medpath.com/news/sonomotion-announces-fda-de-novo-clearance-for-its-stone-cleartm-device 2024-11-13T17:06:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sonomotion-announces-fda-de-novo-clearance-for-its-stone-cleartm-device 2024-11-13T17:06:45+00:00 weekly 0.7 https://trial.medpath.com/news/pimicotinib-significantly-improves-responses-vs-placebo-in-tgct-cancer-network 2024-11-13T17:06:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pimicotinib-significantly-improves-responses-vs-placebo-in-tgct-cancer-network 2024-11-13T17:06:05+00:00 weekly 0.7 https://trial.medpath.com/news/phaxiam-reports-third-quarter-2024-financial-information-stock-titan 2024-11-13T17:04:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phaxiam-reports-third-quarter-2024-financial-information-stock-titan 2024-11-13T17:04:58+00:00 weekly 0.7 https://trial.medpath.com/news/valneva-and-limmatech-announce-first-vaccination-in-phase-2b-human-challenge-study 2024-11-13T16:48:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/valneva-and-limmatech-announce-first-vaccination-in-phase-2b-human-challenge-study 2024-11-13T16:48:43+00:00 weekly 0.7 https://trial.medpath.com/news/lenacapavir-for-prep-demonstrates-strong-efficacy-adherence-in-phase-3-trial 2024-11-13T16:48:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lenacapavir-for-prep-demonstrates-strong-efficacy-adherence-in-phase-3-trial 2024-11-13T16:48:29+00:00 weekly 0.7 https://trial.medpath.com/news/phaxiam-reports-third-quarter-2024-financial-information-globenewswire 2024-11-13T16:47:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phaxiam-reports-third-quarter-2024-financial-information-globenewswire 2024-11-13T16:47:20+00:00 weekly 0.7 https://trial.medpath.com/news/fda-rejects-full-approval-of-ocaliva-as-second-line-pbc-treatment-liver-disease-news 2024-11-13T16:42:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-rejects-full-approval-of-ocaliva-as-second-line-pbc-treatment-liver-disease-news 2024-11-13T16:42:24+00:00 weekly 0.7 https://trial.medpath.com/news/boehringer-ingelheim-and-mtm-vision-join-forces-to-combat-vision-loss-from-diabetes 2024-11-13T16:29:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boehringer-ingelheim-and-mtm-vision-join-forces-to-combat-vision-loss-from-diabetes 2024-11-13T16:29:39+00:00 weekly 0.7 https://trial.medpath.com/news/livanova-hits-goals-in-sleep-apnea-implant-trial-plans-fda-filing-medtech-dive 2024-11-13T16:26:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/livanova-hits-goals-in-sleep-apnea-implant-trial-plans-fda-filing-medtech-dive 2024-11-13T16:26:25+00:00 weekly 0.7 https://trial.medpath.com/news/chlorhexidine-alcohol-compared-with-povidone-iodine-alcohol-skin-antisepsis-protocols-in 2024-11-13T16:22:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chlorhexidine-alcohol-compared-with-povidone-iodine-alcohol-skin-antisepsis-protocols-in 2024-11-13T16:22:21+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-shares-sink-on-obesity-drug-concerns-astrazeneca-to-spend-3-5b-on-manufacturing 2024-11-13T16:22:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amgen-shares-sink-on-obesity-drug-concerns-astrazeneca-to-spend-3-5b-on-manufacturing 2024-11-13T16:22:11+00:00 weekly 0.7 https://trial.medpath.com/news/recce-pharmaceuticals-receives-approval-for-phase-iii-dfi-trial-in-indonesia 2024-11-13T16:20:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recce-pharmaceuticals-receives-approval-for-phase-iii-dfi-trial-in-indonesia 2024-11-13T16:20:08+00:00 weekly 0.7 https://trial.medpath.com/news/improving-atopic-dermatitis-treatment-for-adolescents-feinberg-news-center 2024-11-13T16:17:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/improving-atopic-dermatitis-treatment-for-adolescents-feinberg-news-center 2024-11-13T16:17:39+00:00 weekly 0.7 https://trial.medpath.com/news/regeneron-sanofi-s-dupixent-approval-signals-major-treatment-breakthrough-for-smokers 2024-11-13T16:12:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regeneron-sanofi-s-dupixent-approval-signals-major-treatment-breakthrough-for-smokers 2024-11-13T16:12:59+00:00 weekly 0.7 https://trial.medpath.com/news/ozempic-may-help-curb-alcohol-addiction-study-suggests 2024-11-13T16:11:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ozempic-may-help-curb-alcohol-addiction-study-suggests 2024-11-13T16:11:17+00:00 weekly 0.7 https://trial.medpath.com/news/targeted-magnetic-stimulation-slows-alzheimer-s-progression-in-phase-ii-study 2024-11-13T16:05:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/targeted-magnetic-stimulation-slows-alzheimer-s-progression-in-phase-ii-study 2024-11-13T16:05:12+00:00 weekly 0.7 https://trial.medpath.com/news/recce-pharmaceuticals-receives-approval-for-phase-iii-dfi-trial-in-indonesia 2024-11-13T16:05:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recce-pharmaceuticals-receives-approval-for-phase-iii-dfi-trial-in-indonesia 2024-11-13T16:05:06+00:00 weekly 0.7 https://trial.medpath.com/news/cell-therapy-fights-lethal-childhood-brain-cancer-in-stanford-medicine-trial-news-center 2024-11-13T16:04:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cell-therapy-fights-lethal-childhood-brain-cancer-in-stanford-medicine-trial-news-center 2024-11-13T16:04:30+00:00 weekly 0.7 https://trial.medpath.com/news/intercept-loses-ocaliva-fda-full-approval-bid-in-rare-liver-disease 2024-11-13T15:45:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intercept-loses-ocaliva-fda-full-approval-bid-in-rare-liver-disease 2024-11-13T15:45:34+00:00 weekly 0.7 https://trial.medpath.com/news/non-cystic-fibrosis-bronchiectasis-pipeline-insight-over-globenewswire 2024-11-13T15:38:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/non-cystic-fibrosis-bronchiectasis-pipeline-insight-over-globenewswire 2024-11-13T15:38:07+00:00 weekly 0.7 https://trial.medpath.com/news/minoryx-ceo-marc-martinell-discusses-a-new-small-molecule-therapeutic-for-ald 2024-11-13T15:33:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/minoryx-ceo-marc-martinell-discusses-a-new-small-molecule-therapeutic-for-ald 2024-11-13T15:33:50+00:00 weekly 0.7 https://trial.medpath.com/news/komet-phase-iii-trial-of-koselugo-shows-statistically-significant-and-clinically-meaningful 2024-11-13T15:30:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/komet-phase-iii-trial-of-koselugo-shows-statistically-significant-and-clinically-meaningful 2024-11-13T15:30:15+00:00 weekly 0.7 https://trial.medpath.com/news/vergent-bioscience-completes-enrollment-in-phase-2-visualize-trial-evaluating-potential 2024-11-13T15:21:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vergent-bioscience-completes-enrollment-in-phase-2-visualize-trial-evaluating-potential 2024-11-13T15:21:01+00:00 weekly 0.7 https://trial.medpath.com/news/trace-neuroscience-launches-with-101m-and-a-potential-genomic-als-target 2024-11-13T15:20:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trace-neuroscience-launches-with-101m-and-a-potential-genomic-als-target 2024-11-13T15:20:03+00:00 weekly 0.7 https://trial.medpath.com/news/asha-therapeutics-awarded-barnett-drug-development-grant-by-the-als-association-to 2024-11-13T15:07:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/asha-therapeutics-awarded-barnett-drug-development-grant-by-the-als-association-to 2024-11-13T15:07:06+00:00 weekly 0.7 https://trial.medpath.com/news/inmune-bio-inc-announces-final-enrollment-of-208-patients-in-phase-2-trial-in-early 2024-11-13T15:07:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inmune-bio-inc-announces-final-enrollment-of-208-patients-in-phase-2-trial-in-early 2024-11-13T15:07:06+00:00 weekly 0.7 https://trial.medpath.com/news/precision-medicine-in-nsclc-the-power-of-molecular-testing-cancer-network 2024-11-13T15:06:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/precision-medicine-in-nsclc-the-power-of-molecular-testing-cancer-network 2024-11-13T15:06:18+00:00 weekly 0.7 https://trial.medpath.com/news/health-canada-approves-gsk-s-ojjaara-for-myelofibrosis-in-anaemia-patients 2024-11-13T15:01:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/health-canada-approves-gsk-s-ojjaara-for-myelofibrosis-in-anaemia-patients 2024-11-13T15:01:13+00:00 weekly 0.7 https://trial.medpath.com/news/induction-of-cure-in-early-arthritis-i-cea-study-protocol-for-an-investigator-initiated-trials 2024-11-13T14:38:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/induction-of-cure-in-early-arthritis-i-cea-study-protocol-for-an-investigator-initiated-trials 2024-11-13T14:38:46+00:00 weekly 0.7 https://trial.medpath.com/news/asha-therapeutics-secures-als-grant-for-breakthrough-sarm1-drug-development 2024-11-13T14:36:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/asha-therapeutics-secures-als-grant-for-breakthrough-sarm1-drug-development 2024-11-13T14:36:43+00:00 weekly 0.7 https://trial.medpath.com/news/lexaria-s-dehydratech-diabetes-study-advances-fda-track-phase-1b-trial-gets-key-approval 2024-11-13T14:36:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lexaria-s-dehydratech-diabetes-study-advances-fda-track-phase-1b-trial-gets-key-approval 2024-11-13T14:36:41+00:00 weekly 0.7 https://trial.medpath.com/news/rejuvenating-lung-stem-cells-for-idiopathic-pulmonary-fibrosis-drug-discovery-news 2024-11-13T14:24:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rejuvenating-lung-stem-cells-for-idiopathic-pulmonary-fibrosis-drug-discovery-news 2024-11-13T14:24:08+00:00 weekly 0.7 https://trial.medpath.com/news/atai-life-sciences-advances-therapeutic-pipeline-in-q3-with-fda-approval-of-vls-01 2024-11-13T14:22:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/atai-life-sciences-advances-therapeutic-pipeline-in-q3-with-fda-approval-of-vls-01 2024-11-13T14:22:30+00:00 weekly 0.7 https://trial.medpath.com/news/inmune-bio-hits-major-milestone-208-patients-enrolled-in-phase-2-alzheimer-s-trial 2024-11-13T14:14:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inmune-bio-hits-major-milestone-208-patients-enrolled-in-phase-2-alzheimer-s-trial 2024-11-13T14:14:45+00:00 weekly 0.7 https://trial.medpath.com/news/med-el-corporation-announces-fda-approval-of-expanded-candidacy-indications-morningstar 2024-11-13T14:08:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/med-el-corporation-announces-fda-approval-of-expanded-candidacy-indications-morningstar 2024-11-13T14:08:37+00:00 weekly 0.7 https://trial.medpath.com/news/helix-debuts-novel-precision-effectiveness-model-that-predicts-12-month-weight-loss 2024-11-13T14:06:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/helix-debuts-novel-precision-effectiveness-model-that-predicts-12-month-weight-loss 2024-11-13T14:06:57+00:00 weekly 0.7 https://trial.medpath.com/news/inmune-bio-inc-announces-final-enrollment-of-208-patients-globenewswire 2024-11-13T14:05:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inmune-bio-inc-announces-final-enrollment-of-208-patients-globenewswire 2024-11-13T14:05:17+00:00 weekly 0.7 https://trial.medpath.com/news/gemvax-kael-announces-results-from-phase-2a-clinical-trial-for-psp-aftd 2024-11-13T14:01:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gemvax-kael-announces-results-from-phase-2a-clinical-trial-for-psp-aftd 2024-11-13T14:01:01+00:00 weekly 0.7 https://trial.medpath.com/news/ge-healthcare-gets-fda-approval-for-head-only-mri-scanner-morningstar 2024-11-13T13:58:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ge-healthcare-gets-fda-approval-for-head-only-mri-scanner-morningstar 2024-11-13T13:58:34+00:00 weekly 0.7 https://trial.medpath.com/news/intelligent-bio-solutions-hits-major-breakthrough-in-drug-detection-study-fda-filing-next 2024-11-13T13:38:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intelligent-bio-solutions-hits-major-breakthrough-in-drug-detection-study-fda-filing-next 2024-11-13T13:38:22+00:00 weekly 0.7 https://trial.medpath.com/news/syros-stock-craters-after-lead-cancer-therapy-flops-in-phase-iii-trial-yahoo-finance 2024-11-13T13:32:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syros-stock-craters-after-lead-cancer-therapy-flops-in-phase-iii-trial-yahoo-finance 2024-11-13T13:32:41+00:00 weekly 0.7 https://trial.medpath.com/news/ibi354-shows-efficacy-and-safety-in-her2-and-her2-low-advanced-breast-cancer 2024-11-13T13:27:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ibi354-shows-efficacy-and-safety-in-her2-and-her2-low-advanced-breast-cancer 2024-11-13T13:27:58+00:00 weekly 0.7 https://trial.medpath.com/news/longboard-commences-phase-iii-trial-of-bexicaserin-for-dees-seizure-treatment 2024-11-13T13:24:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/longboard-commences-phase-iii-trial-of-bexicaserin-for-dees-seizure-treatment 2024-11-13T13:24:18+00:00 weekly 0.7 https://trial.medpath.com/news/biorestorative-therapies-inc-reports-positive-preliminary-phase-2-brtx-100-clinical-data 2024-11-13T13:19:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biorestorative-therapies-inc-reports-positive-preliminary-phase-2-brtx-100-clinical-data 2024-11-13T13:19:40+00:00 weekly 0.7 https://trial.medpath.com/news/cardiol-therapeutics-inc-added-to-prism-emerging-biotech-index-globenewswire 2024-11-13T13:15:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cardiol-therapeutics-inc-added-to-prism-emerging-biotech-index-globenewswire 2024-11-13T13:15:50+00:00 weekly 0.7 https://trial.medpath.com/news/inovio-s-ino-3107-shows-breakthrough-immune-response-in-rrp-treatment-trial 2024-11-13T13:15:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inovio-s-ino-3107-shows-breakthrough-immune-response-in-rrp-treatment-trial 2024-11-13T13:15:06+00:00 weekly 0.7 https://trial.medpath.com/news/moonlake-immunotherapeutics-starts-phase-3-izar-program-of-globenewswire 2024-11-13T13:14:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moonlake-immunotherapeutics-starts-phase-3-izar-program-of-globenewswire 2024-11-13T13:14:28+00:00 weekly 0.7 https://trial.medpath.com/news/med-el-corporation-announces-fda-approval-of-expanded-candidacy-indications-and 2024-11-13T13:10:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/med-el-corporation-announces-fda-approval-of-expanded-candidacy-indications-and 2024-11-13T13:10:53+00:00 weekly 0.7 https://trial.medpath.com/news/enveda-announces-first-candidate-discovered-from-nature-using-ai-advances-to-clinical-trials 2024-11-13T13:10:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enveda-announces-first-candidate-discovered-from-nature-using-ai-advances-to-clinical-trials 2024-11-13T13:10:26+00:00 weekly 0.7 https://trial.medpath.com/news/smartcardia-receives-fda-clearance-for-outpatient-cardiac-telemetry-for-its-7-lead-ecg 2024-11-13T13:01:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/smartcardia-receives-fda-clearance-for-outpatient-cardiac-telemetry-for-its-7-lead-ecg 2024-11-13T13:01:31+00:00 weekly 0.7 https://trial.medpath.com/news/shilpa-medicare-s-acceptance-by-usfda-of-nda-filed-by-its-cdmo-partner-unicycive-for 2024-11-13T12:55:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shilpa-medicare-s-acceptance-by-usfda-of-nda-filed-by-its-cdmo-partner-unicycive-for 2024-11-13T12:55:44+00:00 weekly 0.7 https://trial.medpath.com/news/cybin-initiates-paradigm-a-multinational-pivotal-phase-3-program-evaluating-cyb003-for 2024-11-13T12:50:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cybin-initiates-paradigm-a-multinational-pivotal-phase-3-program-evaluating-cyb003-for 2024-11-13T12:50:24+00:00 weekly 0.7 https://trial.medpath.com/news/mural-oncology-announces-third-quarter-2024-financial-results-and-provides-update-on 2024-11-13T12:41:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mural-oncology-announces-third-quarter-2024-financial-results-and-provides-update-on 2024-11-13T12:41:11+00:00 weekly 0.7 https://trial.medpath.com/news/cybin-initiates-paradigm-a-multinational-pivotal-phase-3-program-evaluating-cyb003-for 2024-11-13T12:40:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cybin-initiates-paradigm-a-multinational-pivotal-phase-3-program-evaluating-cyb003-for 2024-11-13T12:40:49+00:00 weekly 0.7 https://trial.medpath.com/news/jeremie-calais-md-highlights-study-of-psma-pet-vs-bone-scan-in-metastatic-prostate-cancer 2024-11-13T12:33:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jeremie-calais-md-highlights-study-of-psma-pet-vs-bone-scan-in-metastatic-prostate-cancer 2024-11-13T12:33:52+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-s-nipocalimab-granted-fda-breakthrough-designation-for-sjogren-s-disease-pmlive 2024-11-13T12:24:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-s-nipocalimab-granted-fda-breakthrough-designation-for-sjogren-s-disease-pmlive 2024-11-13T12:24:55+00:00 weekly 0.7 https://trial.medpath.com/news/unicycive-announces-third-quarter-2024-financial-results-and-provides-business-update 2024-11-13T12:24:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/unicycive-announces-third-quarter-2024-financial-results-and-provides-business-update 2024-11-13T12:24:16+00:00 weekly 0.7 https://trial.medpath.com/news/polypid-provides-corporate-update-and-reports-third-quarter-2024-financial-results 2024-11-13T12:15:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/polypid-provides-corporate-update-and-reports-third-quarter-2024-financial-results 2024-11-13T12:15:08+00:00 weekly 0.7 https://trial.medpath.com/news/leap-therapeutics-reports-third-quarter-2024-financial-results-stock-titan 2024-11-13T12:12:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leap-therapeutics-reports-third-quarter-2024-financial-results-stock-titan 2024-11-13T12:12:18+00:00 weekly 0.7 https://trial.medpath.com/news/longboard-commences-phase-iii-trial-of-bexicaserin-for-dees-seizure-treatment 2024-11-13T12:07:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/longboard-commences-phase-iii-trial-of-bexicaserin-for-dees-seizure-treatment 2024-11-13T12:07:27+00:00 weekly 0.7 https://trial.medpath.com/news/syros-stock-craters-after-lead-cancer-therapy-flops-in-phase-iii-trial 2024-11-13T11:53:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syros-stock-craters-after-lead-cancer-therapy-flops-in-phase-iii-trial 2024-11-13T11:53:09+00:00 weekly 0.7 https://trial.medpath.com/news/x4-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-13T11:51:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/x4-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-13T11:51:24+00:00 weekly 0.7 https://trial.medpath.com/news/immunic-announces-publication-of-data-from-phase-1-1b-clinical-trial-of-imu-856-pr-newswire 2024-11-13T11:44:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunic-announces-publication-of-data-from-phase-1-1b-clinical-trial-of-imu-856-pr-newswire 2024-11-13T11:44:37+00:00 weekly 0.7 https://trial.medpath.com/news/gyre-therapeutics-reports-third-quarter-2024-and-year-to-date-financial-results-and 2024-11-13T11:18:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gyre-therapeutics-reports-third-quarter-2024-and-year-to-date-financial-results-and 2024-11-13T11:18:00+00:00 weekly 0.7 https://trial.medpath.com/news/gyre-therapeutics-reports-third-quarter-2024-and-globenewswire 2024-11-13T11:17:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gyre-therapeutics-reports-third-quarter-2024-and-globenewswire 2024-11-13T11:17:16+00:00 weekly 0.7 https://trial.medpath.com/news/genascence-granted-fda-fast-track-designation-for-gnsc-001-in-patients-with-biospace 2024-11-13T11:01:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genascence-granted-fda-fast-track-designation-for-gnsc-001-in-patients-with-biospace 2024-11-13T11:01:32+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-seek-approval-for-first-drug-to-treat-high-risk-smoldering-myeloma-pharmafile 2024-11-13T10:52:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-seek-approval-for-first-drug-to-treat-high-risk-smoldering-myeloma-pharmafile 2024-11-13T10:52:18+00:00 weekly 0.7 https://trial.medpath.com/news/azitra-inc-announces-q3-2024-financial-results-and-provides-business-updates 2024-11-13T10:21:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/azitra-inc-announces-q3-2024-financial-results-and-provides-business-updates 2024-11-13T10:21:15+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-provides-statement-on-maritide-phase-1-data 2024-11-13T10:20:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amgen-provides-statement-on-maritide-phase-1-data 2024-11-13T10:20:23+00:00 weekly 0.7 https://trial.medpath.com/news/immuneonco-advances-cancer-drug-trials-with-promising-results-tipranks-com 2024-11-13T10:13:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immuneonco-advances-cancer-drug-trials-with-promising-results-tipranks-com 2024-11-13T10:13:57+00:00 weekly 0.7 https://trial.medpath.com/news/menin-suits-syndax-s-revumenib-phase-ii-win-in-aml-measured-bioworld 2024-11-13T09:57:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/menin-suits-syndax-s-revumenib-phase-ii-win-in-aml-measured-bioworld 2024-11-13T09:57:58+00:00 weekly 0.7 https://trial.medpath.com/news/mediprint-ophthalmics-reveals-positive-results-from-phase-2b-study-of-ll-bmt1-contact-lens 2024-11-13T09:55:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mediprint-ophthalmics-reveals-positive-results-from-phase-2b-study-of-ll-bmt1-contact-lens 2024-11-13T09:55:41+00:00 weekly 0.7 https://trial.medpath.com/news/a-phase-i-ii-clinical-study-of-anti-her2-bispecific-adc-subcutaneous-co-formulation 2024-11-13T09:39:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-phase-i-ii-clinical-study-of-anti-her2-bispecific-adc-subcutaneous-co-formulation 2024-11-13T09:39:12+00:00 weekly 0.7 https://trial.medpath.com/news/curateq-biologics-gains-ema-gmp-certification-for-biosimilars-facility 2024-11-13T09:33:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/curateq-biologics-gains-ema-gmp-certification-for-biosimilars-facility 2024-11-13T09:33:32+00:00 weekly 0.7 https://trial.medpath.com/news/astrazenecas-contribution-to-the-breast-cancer-market-precedence-research 2024-11-13T09:15:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazenecas-contribution-to-the-breast-cancer-market-precedence-research 2024-11-13T09:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/topical-drug-combos-may-be-beneficial-for-cipn-oncology-nursing-news 2024-11-13T09:06:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/topical-drug-combos-may-be-beneficial-for-cipn-oncology-nursing-news 2024-11-13T09:06:24+00:00 weekly 0.7 https://trial.medpath.com/news/microbiotica-doses-first-patient-in-phase-1b-trial-of-mb310-precision-microbiome-therapy-for-ulcerative-colitis 2024-11-13T09:00:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/microbiotica-doses-first-patient-in-phase-1b-trial-of-mb310-precision-microbiome-therapy-for-ulcerative-colitis 2024-11-13T09:00:06+00:00 weekly 0.7 https://trial.medpath.com/news/global-pharma-s-investment-in-korean-clinical-research-grew-7-in-2023-krpia-kbr 2024-11-13T08:33:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-pharma-s-investment-in-korean-clinical-research-grew-7-in-2023-krpia-kbr 2024-11-13T08:33:43+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-grants-breakthrough-therapy-designation-to-johnson-johnson-s-nipocalimab-to 2024-11-13T08:31:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-fda-grants-breakthrough-therapy-designation-to-johnson-johnson-s-nipocalimab-to 2024-11-13T08:31:12+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-clears-investigational-new-drug-application-for-crispr-cas13-rna-editing-therapy 2024-11-13T08:21:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-fda-clears-investigational-new-drug-application-for-crispr-cas13-rna-editing-therapy 2024-11-13T08:21:45+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-drug-pembrolizumab-improves-outcomes-for-patients-with-soft-tissue-sarcoma 2024-11-13T08:20:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunotherapy-drug-pembrolizumab-improves-outcomes-for-patients-with-soft-tissue-sarcoma 2024-11-13T08:20:01+00:00 weekly 0.7 https://trial.medpath.com/news/lyophilization-drives-15-annual-growth-in-novel-drug-approvals-reshaping-pharmaceutical-manufacturing 2024-11-13T08:02:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lyophilization-drives-15-annual-growth-in-novel-drug-approvals-reshaping-pharmaceutical-manufacturing 2024-11-13T08:02:05+00:00 weekly 0.7 https://trial.medpath.com/news/glucose-responsive-insulin-for-diabetes-nature-biotechnology 2024-11-13T07:15:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glucose-responsive-insulin-for-diabetes-nature-biotechnology 2024-11-13T07:15:26+00:00 weekly 0.7 https://trial.medpath.com/news/pimicotinib-significantly-improved-outcomes-for-patients-with-tenosynovial-giant-cell 2024-11-13T06:40:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pimicotinib-significantly-improved-outcomes-for-patients-with-tenosynovial-giant-cell 2024-11-13T06:40:52+00:00 weekly 0.7 https://trial.medpath.com/news/myriad-genetics-expands-prenatal-testing-access-with-retail-launch-of-sneakpeek-early-fetal-sex-test 2024-11-13T06:10:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/myriad-genetics-expands-prenatal-testing-access-with-retail-launch-of-sneakpeek-early-fetal-sex-test 2024-11-13T06:10:25+00:00 weekly 0.7 https://trial.medpath.com/news/moleculin-receives-institutional-review-board-approval-for-miracle-phase-3-pivotal-trial 2024-11-13T05:56:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moleculin-receives-institutional-review-board-approval-for-miracle-phase-3-pivotal-trial 2024-11-13T05:56:25+00:00 weekly 0.7 https://trial.medpath.com/news/caliway-announced-ema-orphan-drug-designation-granted-to-cbl-514-for-dercum-s 2024-11-13T05:45:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/caliway-announced-ema-orphan-drug-designation-granted-to-cbl-514-for-dercum-s 2024-11-13T05:45:05+00:00 weekly 0.7 https://trial.medpath.com/news/caliway-announced-ema-orphan-drug-designation-granted-to-cbl-514-for-dercum-s 2024-11-13T05:38:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/caliway-announced-ema-orphan-drug-designation-granted-to-cbl-514-for-dercum-s 2024-11-13T05:38:16+00:00 weekly 0.7 https://trial.medpath.com/news/arch-biopartners-doses-first-patient-in-canada-for-phase-ii-trial-of-lsalt-peptide-to-treat 2024-11-13T05:31:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arch-biopartners-doses-first-patient-in-canada-for-phase-ii-trial-of-lsalt-peptide-to-treat 2024-11-13T05:31:11+00:00 weekly 0.7 https://trial.medpath.com/news/regulator-defends-new-drug-approval-fee-hike-plans-faster-review-process-kbr 2024-11-13T05:25:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regulator-defends-new-drug-approval-fee-hike-plans-faster-review-process-kbr 2024-11-13T05:25:50+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-novavax-to-resume-trials-of-covid-19-and-flu-combo-vaccine 2024-11-13T04:59:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-novavax-to-resume-trials-of-covid-19-and-flu-combo-vaccine 2024-11-13T04:59:07+00:00 weekly 0.7 https://trial.medpath.com/news/revumenib-shows-promise-in-aml-trial-phase-2-results-investing-com 2024-11-13T04:59:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/revumenib-shows-promise-in-aml-trial-phase-2-results-investing-com 2024-11-13T04:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/novavax-resumes-phase-3-vaccine-trials-after-fda-hold-tipranks-com 2024-11-13T04:50:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novavax-resumes-phase-3-vaccine-trials-after-fda-hold-tipranks-com 2024-11-13T04:50:25+00:00 weekly 0.7 https://trial.medpath.com/news/spinal-cord-injury-clinical-trials-2024-ema-pdma-fda-openpr-com 2024-11-13T04:49:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spinal-cord-injury-clinical-trials-2024-ema-pdma-fda-openpr-com 2024-11-13T04:49:14+00:00 weekly 0.7 https://trial.medpath.com/news/advancements-in-tenosynovial-giant-cell-tumors-clinical-trials-highlighted-for-2024 2024-11-13T04:37:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advancements-in-tenosynovial-giant-cell-tumors-clinical-trials-highlighted-for-2024 2024-11-13T04:37:52+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-regeneron-pharmaceuticals-dupixent-approval-marks-a-significant-shift-pr-newswire 2024-11-13T04:32:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sanofi-regeneron-pharmaceuticals-dupixent-approval-marks-a-significant-shift-pr-newswire 2024-11-13T04:32:02+00:00 weekly 0.7 https://trial.medpath.com/news/calidi-biotherapeutics-reports-third-quarter-2024-operating-and-financial-results 2024-11-13T04:19:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/calidi-biotherapeutics-reports-third-quarter-2024-operating-and-financial-results 2024-11-13T04:19:37+00:00 weekly 0.7 https://trial.medpath.com/news/advancements-in-traumatic-brain-injury-clinical-trials-highlighted-for-2024 2024-11-13T04:11:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advancements-in-traumatic-brain-injury-clinical-trials-highlighted-for-2024 2024-11-13T04:11:45+00:00 weekly 0.7 https://trial.medpath.com/news/china-s-anti-espionage-law-threatens-global-pharmaceutical-supply-chain-security 2024-11-13T04:06:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/china-s-anti-espionage-law-threatens-global-pharmaceutical-supply-chain-security 2024-11-13T04:06:33+00:00 weekly 0.7 https://trial.medpath.com/news/zevra-therapeutics-reports-third-quarter-2024-financial-results-and-corporate-updates 2024-11-13T03:49:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zevra-therapeutics-reports-third-quarter-2024-financial-results-and-corporate-updates 2024-11-13T03:49:37+00:00 weekly 0.7 https://trial.medpath.com/news/nxera-pharma-s-partner-centessa-initiates-phase-2-trial-with-orx750-a-novel-orexin 2024-11-13T03:49:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nxera-pharma-s-partner-centessa-initiates-phase-2-trial-with-orx750-a-novel-orexin 2024-11-13T03:49:34+00:00 weekly 0.7 https://trial.medpath.com/news/a-phase-i-ii-clinical-study-of-anti-her2-bispecific-adc-subcutaneous-co-formulation 2024-11-13T03:34:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-phase-i-ii-clinical-study-of-anti-her2-bispecific-adc-subcutaneous-co-formulation 2024-11-13T03:34:17+00:00 weekly 0.7 https://trial.medpath.com/news/safety-reporting-in-trials-on-glaucoma-interventions-registered-in-clinicaltrials-gov-and 2024-11-13T03:20:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/safety-reporting-in-trials-on-glaucoma-interventions-registered-in-clinicaltrials-gov-and 2024-11-13T03:20:30+00:00 weekly 0.7 https://trial.medpath.com/news/regulator-and-funder-fda-s-orphan-products-grants-program-awards-significant-funding 2024-11-13T02:57:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regulator-and-funder-fda-s-orphan-products-grants-program-awards-significant-funding 2024-11-13T02:57:42+00:00 weekly 0.7 https://trial.medpath.com/news/a-phase-i-ii-clinical-study-of-anti-her2-bispecific-adc-subcutaneous-co-pr-newswire 2024-11-13T02:50:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-phase-i-ii-clinical-study-of-anti-her2-bispecific-adc-subcutaneous-co-pr-newswire 2024-11-13T02:50:28+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-kebilidi-eladocagene-exuparvovec-tneq-gene-therapy-for-the-treatment-of-aadc-deficiency 2024-11-13T02:11:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-kebilidi-eladocagene-exuparvovec-tneq-gene-therapy-for-the-treatment-of-aadc-deficiency 2024-11-13T02:11:31+00:00 weekly 0.7 https://trial.medpath.com/news/nivolumab-chemotherapy-combo-boosts-pfs-in-chl-poised-for-standard-use 2024-11-13T02:08:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nivolumab-chemotherapy-combo-boosts-pfs-in-chl-poised-for-standard-use 2024-11-13T02:08:10+00:00 weekly 0.7 https://trial.medpath.com/news/earnings-call-legend-biotech-sees-robust-growth-in-carvykti-sales-investing-com 2024-11-13T01:37:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/earnings-call-legend-biotech-sees-robust-growth-in-carvykti-sales-investing-com 2024-11-13T01:37:55+00:00 weekly 0.7 https://trial.medpath.com/news/elraglusib-gains-fda-rare-pediatric-disease-designation-in-ewing-sarcoma 2024-11-13T01:09:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elraglusib-gains-fda-rare-pediatric-disease-designation-in-ewing-sarcoma 2024-11-13T01:09:15+00:00 weekly 0.7 https://trial.medpath.com/news/a-scrap-of-data-on-amgen-s-obesity-drug-maritide-wipes-out-12b-in-market-value-stat-news 2024-11-13T01:03:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-scrap-of-data-on-amgen-s-obesity-drug-maritide-wipes-out-12b-in-market-value-stat-news 2024-11-13T01:03:08+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-the-first-flu-vaccine-for-at-home-use-providing-a-needle-free-option-mondaq 2024-11-13T00:41:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-the-first-flu-vaccine-for-at-home-use-providing-a-needle-free-option-mondaq 2024-11-13T00:41:17+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-explores-sale-of-hospital-drugs-unit-amid-strategic-restructuring 2024-11-13T00:36:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-explores-sale-of-hospital-drugs-unit-amid-strategic-restructuring 2024-11-13T00:36:50+00:00 weekly 0.7 https://trial.medpath.com/news/lung-cancer-takes-big-beating-from-tiny-nano-particles-synbiobeta 2024-11-13T00:21:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lung-cancer-takes-big-beating-from-tiny-nano-particles-synbiobeta 2024-11-13T00:21:09+00:00 weekly 0.7 https://trial.medpath.com/news/comparison-of-drug-eluting-bead-transarterial-chemoembolization-combined-with-apatinib-nature 2024-11-13T00:08:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/comparison-of-drug-eluting-bead-transarterial-chemoembolization-combined-with-apatinib-nature 2024-11-13T00:08:01+00:00 weekly 0.7 https://trial.medpath.com/news/acurx-pharma-q3-new-patent-win-trial-progress-despite-cash-decline 2024-11-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acurx-pharma-q3-new-patent-win-trial-progress-despite-cash-decline 2024-11-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/regeneron-to-highlight-pioneering-pipeline-progress-across-multiple-modalities-spanning-10-types-of-blood-cancers-and-disorders-at-ash 2024-11-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regeneron-to-highlight-pioneering-pipeline-progress-across-multiple-modalities-spanning-10-types-of-blood-cancers-and-disorders-at-ash 2024-11-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/acumen-pharmaceuticals-inc-sec-10-q-report-tradingview 2024-11-12T23:53:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acumen-pharmaceuticals-inc-sec-10-q-report-tradingview 2024-11-12T23:53:10+00:00 weekly 0.7 https://trial.medpath.com/news/a-revolution-in-antibody-therapy-q-a-with-randy-noelle-phd-geisel-news 2024-11-12T23:50:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-revolution-in-antibody-therapy-q-a-with-randy-noelle-phd-geisel-news 2024-11-12T23:50:21+00:00 weekly 0.7 https://trial.medpath.com/news/pivotal-clinical-trial-of-descartes-08-for-mg-may-start-in-2025-myasthenia-gravis-news 2024-11-12T23:40:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pivotal-clinical-trial-of-descartes-08-for-mg-may-start-in-2025-myasthenia-gravis-news 2024-11-12T23:40:13+00:00 weekly 0.7 https://trial.medpath.com/news/huidagene-therapeutics-ind-application-for-hg202-for-the-treatment-of-namd-cleared-by-fda 2024-11-12T23:35:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/huidagene-therapeutics-ind-application-for-hg202-for-the-treatment-of-namd-cleared-by-fda 2024-11-12T23:35:31+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-validation-and-real-world-impact-of-precivityad2-test-for-alzheimer-diagnosis 2024-11-12T23:33:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-validation-and-real-world-impact-of-precivityad2-test-for-alzheimer-diagnosis 2024-11-12T23:33:37+00:00 weekly 0.7 https://trial.medpath.com/news/repare-therapeutics-announces-agreement-with-the-us-national-cancer-institute-to 2024-11-12T23:29:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/repare-therapeutics-announces-agreement-with-the-us-national-cancer-institute-to 2024-11-12T23:29:40+00:00 weekly 0.7 https://trial.medpath.com/news/eupraxia-s-eoe-drug-shows-breakthrough-results-complete-remission-in-latest-trial-data 2024-11-12T23:20:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eupraxia-s-eoe-drug-shows-breakthrough-results-complete-remission-in-latest-trial-data 2024-11-12T23:20:35+00:00 weekly 0.7 https://trial.medpath.com/news/fda-sets-pfuda-date-accepts-bla-submission-for-pz-cel-in-epidermolysis-bullosa 2024-11-12T23:10:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-sets-pfuda-date-accepts-bla-submission-for-pz-cel-in-epidermolysis-bullosa 2024-11-12T23:10:15+00:00 weekly 0.7 https://trial.medpath.com/news/fox-chase-cancer-center-s-dr-vanessa-wookey-presents-rectal-cancer-research-at-24th 2024-11-12T23:05:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fox-chase-cancer-center-s-dr-vanessa-wookey-presents-rectal-cancer-research-at-24th 2024-11-12T23:05:48+00:00 weekly 0.7 https://trial.medpath.com/news/antelope-surgical-solutions-achieves-commercial-investigational-new-drug-ind-approval 2024-11-12T23:05:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/antelope-surgical-solutions-achieves-commercial-investigational-new-drug-ind-approval 2024-11-12T23:05:23+00:00 weekly 0.7 https://trial.medpath.com/news/rare-disease-clinical-trials-face-logistical-challenges-experts-to-address-solutions-at-brussels-conference 2024-11-12T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rare-disease-clinical-trials-face-logistical-challenges-experts-to-address-solutions-at-brussels-conference 2024-11-12T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-receives-new-bla-for-dato-dxd-in-pretreated-egfr-advanced-nsclc-onclive 2024-11-12T22:44:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-receives-new-bla-for-dato-dxd-in-pretreated-egfr-advanced-nsclc-onclive 2024-11-12T22:44:08+00:00 weekly 0.7 https://trial.medpath.com/news/selumetinib-boosts-orr-in-nf1-with-inoperable-plexiform-neurofibroma-onclive 2024-11-12T22:40:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/selumetinib-boosts-orr-in-nf1-with-inoperable-plexiform-neurofibroma-onclive 2024-11-12T22:40:17+00:00 weekly 0.7 https://trial.medpath.com/news/fda-rejects-full-approval-of-liver-disease-drug-medpage-today 2024-11-12T22:22:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-rejects-full-approval-of-liver-disease-drug-medpage-today 2024-11-12T22:22:08+00:00 weekly 0.7 https://trial.medpath.com/news/aura-biosciences-inc-sec-10-q-report-tradingview 2024-11-12T22:21:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aura-biosciences-inc-sec-10-q-report-tradingview 2024-11-12T22:21:00+00:00 weekly 0.7 https://trial.medpath.com/news/azitra-inc-announces-q3-2024-financial-results-and-provides-business-updates 2024-11-12T22:15:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/azitra-inc-announces-q3-2024-financial-results-and-provides-business-updates 2024-11-12T22:15:45+00:00 weekly 0.7 https://trial.medpath.com/news/3-things-to-know-about-cobenfy-the-new-schizophrenia-drug-yale-medicine 2024-11-12T22:13:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/3-things-to-know-about-cobenfy-the-new-schizophrenia-drug-yale-medicine 2024-11-12T22:13:53+00:00 weekly 0.7 https://trial.medpath.com/news/new-treatment-combination-improves-outcomes-for-small-cell-bladder-and-prostate-cancer-patients 2024-11-12T22:10:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-treatment-combination-improves-outcomes-for-small-cell-bladder-and-prostate-cancer-patients 2024-11-12T22:10:09+00:00 weekly 0.7 https://trial.medpath.com/news/gene-therapy-cap-002-gains-fda-orphan-drug-designation-for-stxbp1-developmental 2024-11-12T22:08:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gene-therapy-cap-002-gains-fda-orphan-drug-designation-for-stxbp1-developmental 2024-11-12T22:08:18+00:00 weekly 0.7 https://trial.medpath.com/news/eyenovia-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-12T21:46:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eyenovia-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-12T21:46:32+00:00 weekly 0.7 https://trial.medpath.com/news/new-blood-test-detects-early-lung-damage-in-cancer-patients-on-targeted-therapy 2024-11-12T21:43:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-blood-test-detects-early-lung-damage-in-cancer-patients-on-targeted-therapy 2024-11-12T21:43:58+00:00 weekly 0.7 https://trial.medpath.com/news/collaboration-to-support-phase-3-secure-trial-of-67cu-sar-bispsma-urology-times 2024-11-12T21:36:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/collaboration-to-support-phase-3-secure-trial-of-67cu-sar-bispsma-urology-times 2024-11-12T21:36:01+00:00 weekly 0.7 https://trial.medpath.com/news/lisata-therapeutics-advances-clinical-trials-in-q3-ahead-of-data-rich-2025-nasdaq-lsta 2024-11-12T21:32:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lisata-therapeutics-advances-clinical-trials-in-q3-ahead-of-data-rich-2025-nasdaq-lsta 2024-11-12T21:32:47+00:00 weekly 0.7 https://trial.medpath.com/news/crinetics-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides 2024-11-12T21:29:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/crinetics-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides 2024-11-12T21:29:05+00:00 weekly 0.7 https://trial.medpath.com/news/oncocyte-reports-commercial-launch-progress-on-track-to-sign-20-transplant-centers-by 2024-11-12T21:29:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oncocyte-reports-commercial-launch-progress-on-track-to-sign-20-transplant-centers-by 2024-11-12T21:29:02+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-ai-powered-breast-cancer-detection-tech-from-icad-massdevice 2024-11-12T21:22:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-ai-powered-breast-cancer-detection-tech-from-icad-massdevice 2024-11-12T21:22:06+00:00 weekly 0.7 https://trial.medpath.com/news/jenavalve-to-begin-trilogy-heart-valve-trial-massdevice 2024-11-12T21:22:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jenavalve-to-begin-trilogy-heart-valve-trial-massdevice 2024-11-12T21:22:05+00:00 weekly 0.7 https://trial.medpath.com/news/zevra-therapeutics-reports-third-quarter-2024-financial-globenewswire 2024-11-12T21:18:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zevra-therapeutics-reports-third-quarter-2024-financial-globenewswire 2024-11-12T21:18:08+00:00 weekly 0.7 https://trial.medpath.com/news/perspective-therapeutics-reports-267-8m-cash-position-advances-cancer-drug-trials 2024-11-12T21:17:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/perspective-therapeutics-reports-267-8m-cash-position-advances-cancer-drug-trials 2024-11-12T21:17:56+00:00 weekly 0.7 https://trial.medpath.com/news/longeveron-r-announces-third-quarter-2024-financial-results-and-provides-business-update 2024-11-12T21:17:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/longeveron-r-announces-third-quarter-2024-financial-results-and-provides-business-update 2024-11-12T21:17:52+00:00 weekly 0.7 https://trial.medpath.com/news/artiva-biotherapeutics-reports-third-quarter-2024-financial-results-and-recent-business-highlights 2024-11-12T21:17:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/artiva-biotherapeutics-reports-third-quarter-2024-financial-results-and-recent-business-highlights 2024-11-12T21:17:52+00:00 weekly 0.7 https://trial.medpath.com/news/aura-biosciences-reports-third-quarter-2024-financial-results-and-business-highlights 2024-11-12T21:17:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aura-biosciences-reports-third-quarter-2024-financial-results-and-business-highlights 2024-11-12T21:17:48+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-renewal-for-canine-chemotherapy-induced-diarrhea-treatment 2024-11-12T21:12:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-renewal-for-canine-chemotherapy-induced-diarrhea-treatment 2024-11-12T21:12:03+00:00 weekly 0.7 https://trial.medpath.com/news/automatic-segmentation-based-multi-modal-radiomics-analysis-of-us-and-mri-for-predicting 2024-11-12T21:11:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/automatic-segmentation-based-multi-modal-radiomics-analysis-of-us-and-mri-for-predicting 2024-11-12T21:11:57+00:00 weekly 0.7 https://trial.medpath.com/news/journey-medical-corporation-reports-third-quarter-2024-globenewswire 2024-11-12T21:11:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/journey-medical-corporation-reports-third-quarter-2024-globenewswire 2024-11-12T21:11:47+00:00 weekly 0.7 https://trial.medpath.com/news/perspective-therapeutics-provides-recent-business-highlights-and-reports-fiscal-3q-2024-results 2024-11-12T21:11:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/perspective-therapeutics-provides-recent-business-highlights-and-reports-fiscal-3q-2024-results 2024-11-12T21:11:11+00:00 weekly 0.7 https://trial.medpath.com/news/corvus-pharmaceuticals-provides-business-update-and-reports-third-quarter-2024-stock-titan 2024-11-12T21:06:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/corvus-pharmaceuticals-provides-business-update-and-reports-third-quarter-2024-stock-titan 2024-11-12T21:06:52+00:00 weekly 0.7 https://trial.medpath.com/news/inflammatix-begins-trial-evaluating-mrna-test-for-patient-infection-status 2024-11-12T21:05:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inflammatix-begins-trial-evaluating-mrna-test-for-patient-infection-status 2024-11-12T21:05:32+00:00 weekly 0.7 https://trial.medpath.com/news/biohaven-announces-third-quarter-2024-financial-results-and-business-developments 2024-11-12T21:05:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biohaven-announces-third-quarter-2024-financial-results-and-business-developments 2024-11-12T21:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/ucl-spinout-autolus-gains-us-approval-for-cancer-therapy 2024-11-12T20:58:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ucl-spinout-autolus-gains-us-approval-for-cancer-therapy 2024-11-12T20:58:54+00:00 weekly 0.7 https://trial.medpath.com/news/dyne-therapeutics-reports-third-quarter-2024-financial-results-and-corporate-update 2024-11-12T20:53:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dyne-therapeutics-reports-third-quarter-2024-financial-results-and-corporate-update 2024-11-12T20:53:35+00:00 weekly 0.7 https://trial.medpath.com/news/milestone-pharmaceuticals-reports-third-quarter-2024-globenewswire 2024-11-12T20:15:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/milestone-pharmaceuticals-reports-third-quarter-2024-globenewswire 2024-11-12T20:15:55+00:00 weekly 0.7 https://trial.medpath.com/news/abeona-therapeutics-announces-fda-acceptance-of-bla-resubmission-of-pz-cel-for-the-treatment-of-recessive-dystrophic-epidermolysis-bullosa 2024-11-12T20:11:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abeona-therapeutics-announces-fda-acceptance-of-bla-resubmission-of-pz-cel-for-the-treatment-of-recessive-dystrophic-epidermolysis-bullosa 2024-11-12T20:11:35+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-announces-koselugo-met-primary-endpoing-in-komet-phase-iii-trial 2024-11-12T20:09:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-announces-koselugo-met-primary-endpoing-in-komet-phase-iii-trial 2024-11-12T20:09:37+00:00 weekly 0.7 https://trial.medpath.com/news/insilico-plans-pivotal-trial-for-ai-based-ipf-candidate 2024-11-12T20:03:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/insilico-plans-pivotal-trial-for-ai-based-ipf-candidate 2024-11-12T20:03:20+00:00 weekly 0.7 https://trial.medpath.com/news/new-study-suggests-weight-loss-drugs-like-ozempic-could-help-with-knee-pain-here-s-why 2024-11-12T19:29:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-study-suggests-weight-loss-drugs-like-ozempic-could-help-with-knee-pain-here-s-why 2024-11-12T19:29:32+00:00 weekly 0.7 https://trial.medpath.com/news/syndax-announces-positive-pivotal-topline-results-from-relapsed-or-refractory-mnpm1-aml-cohort-in-augment-101-trial-of-revumenib 2024-11-12T19:11:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syndax-announces-positive-pivotal-topline-results-from-relapsed-or-refractory-mnpm1-aml-cohort-in-augment-101-trial-of-revumenib 2024-11-12T19:11:17+00:00 weekly 0.7 https://trial.medpath.com/news/drug-for-infertility-puberty-disorders-hot-flashes-soon-us-scientist-times-of-india 2024-11-12T19:05:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/drug-for-infertility-puberty-disorders-hot-flashes-soon-us-scientist-times-of-india 2024-11-12T19:05:45+00:00 weekly 0.7 https://trial.medpath.com/news/abbisko-s-pimicotinib-meets-endpoints-in-phase-iii-bioworld 2024-11-12T19:04:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbisko-s-pimicotinib-meets-endpoints-in-phase-iii-bioworld 2024-11-12T19:04:06+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-schizophrenia-failure-disappoints-but-analysts-show-confidence-in-immunology-portfolio 2024-11-12T19:03:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-s-schizophrenia-failure-disappoints-but-analysts-show-confidence-in-immunology-portfolio 2024-11-12T19:03:33+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-daiichi-sankyo-submit-biologics-license-application-of-datopotamab 2024-11-12T18:50:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-daiichi-sankyo-submit-biologics-license-application-of-datopotamab 2024-11-12T18:50:57+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-wins-fda-ide-for-ottava-surgical-robot-massdevice 2024-11-12T18:50:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-wins-fda-ide-for-ottava-surgical-robot-massdevice 2024-11-12T18:50:02+00:00 weekly 0.7 https://trial.medpath.com/news/first-ever-randomized-clinical-trial-uses-telehealth-for-suicide-prevention-eurekalert 2024-11-12T18:45:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-ever-randomized-clinical-trial-uses-telehealth-for-suicide-prevention-eurekalert 2024-11-12T18:45:23+00:00 weekly 0.7 https://trial.medpath.com/news/gan-lee-pharmaceuticals-announced-positive-phase-1-results-for-its-oral-glp-yahoo-finance 2024-11-12T18:40:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gan-lee-pharmaceuticals-announced-positive-phase-1-results-for-its-oral-glp-yahoo-finance 2024-11-12T18:40:38+00:00 weekly 0.7 https://trial.medpath.com/news/prokidney-reports-third-quarter-2024-financial-results-globenewswire 2024-11-12T18:40:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prokidney-reports-third-quarter-2024-financial-results-globenewswire 2024-11-12T18:40:30+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-autolus-aucatzyl-for-relapsed-refractory-b-cell-acute-lymphoblastic-leukemia 2024-11-12T18:29:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-autolus-aucatzyl-for-relapsed-refractory-b-cell-acute-lymphoblastic-leukemia 2024-11-12T18:29:05+00:00 weekly 0.7 https://trial.medpath.com/news/first-ever-randomized-clinical-trial-uses-telehealth-for-suicide-prevention-ohio-state-medical-center 2024-11-12T18:20:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-ever-randomized-clinical-trial-uses-telehealth-for-suicide-prevention-ohio-state-medical-center 2024-11-12T18:20:32+00:00 weekly 0.7 https://trial.medpath.com/news/protara-therapeutics-inc-sec-10-q-report-tradingview 2024-11-12T18:16:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/protara-therapeutics-inc-sec-10-q-report-tradingview 2024-11-12T18:16:01+00:00 weekly 0.7 https://trial.medpath.com/news/scholar-rock-holding-corp-sec-10-q-report-tradingview 2024-11-12T18:16:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scholar-rock-holding-corp-sec-10-q-report-tradingview 2024-11-12T18:16:00+00:00 weekly 0.7 https://trial.medpath.com/news/datopotamab-deruxtecan-new-bla-submitted-for-accelerated-approval-in-the-us-for-patients-with-previously-treated-advanced-egfr-mutated-non-small-cell-lung-cancer 2024-11-12T18:11:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/datopotamab-deruxtecan-new-bla-submitted-for-accelerated-approval-in-the-us-for-patients-with-previously-treated-advanced-egfr-mutated-non-small-cell-lung-cancer 2024-11-12T18:11:52+00:00 weekly 0.7 https://trial.medpath.com/news/actuate-announces-fda-rare-pediatric-disease-designation-granted-to-elraglusib-for-treatment-of-ewing-sarcoma 2024-11-12T18:11:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/actuate-announces-fda-rare-pediatric-disease-designation-granted-to-elraglusib-for-treatment-of-ewing-sarcoma 2024-11-12T18:11:10+00:00 weekly 0.7 https://trial.medpath.com/news/fda-denies-ocaliva-full-approval-in-primary-biliary-cholangitis-safety-data-still-in-play 2024-11-12T18:10:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-denies-ocaliva-full-approval-in-primary-biliary-cholangitis-safety-data-still-in-play 2024-11-12T18:10:39+00:00 weekly 0.7 https://trial.medpath.com/news/indaptus-therapeutics-inc-sec-10-q-report-tradingview 2024-11-12T18:06:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/indaptus-therapeutics-inc-sec-10-q-report-tradingview 2024-11-12T18:06:29+00:00 weekly 0.7 https://trial.medpath.com/news/naim-alkhouri-md-first-real-world-data-for-resmetirom-use-in-clinical-practice-hcplive 2024-11-12T18:05:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/naim-alkhouri-md-first-real-world-data-for-resmetirom-use-in-clinical-practice-hcplive 2024-11-12T18:05:08+00:00 weekly 0.7 https://trial.medpath.com/news/revumenib-for-npm1-mutant-aml-succeeds-in-pivotal-trial-targeted-oncology 2024-11-12T18:02:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/revumenib-for-npm1-mutant-aml-succeeds-in-pivotal-trial-targeted-oncology 2024-11-12T18:02:09+00:00 weekly 0.7 https://trial.medpath.com/news/key-clinical-compound-updates-from-october-2024 2024-11-12T18:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/key-clinical-compound-updates-from-october-2024 2024-11-12T18:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-cases-in-bluebird-s-gene-therapy-trials-nature-biotechnology 2024-11-12T17:41:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-cases-in-bluebird-s-gene-therapy-trials-nature-biotechnology 2024-11-12T17:41:20+00:00 weekly 0.7 https://trial.medpath.com/news/novel-ai-procured-ism001-055-demonstrates-great-promise-for-treatment-of-ipf 2024-11-12T17:36:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-ai-procured-ism001-055-demonstrates-great-promise-for-treatment-of-ipf 2024-11-12T17:36:25+00:00 weekly 0.7 https://trial.medpath.com/news/cerevance-reports-results-from-trial-of-cvn293-for-neurodegenerative-conditions 2024-11-12T17:33:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cerevance-reports-results-from-trial-of-cvn293-for-neurodegenerative-conditions 2024-11-12T17:33:09+00:00 weekly 0.7 https://trial.medpath.com/news/fda-lifts-clinical-hold-on-combined-covid-19-influenza-vaccine-trials 2024-11-12T17:32:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-lifts-clinical-hold-on-combined-covid-19-influenza-vaccine-trials 2024-11-12T17:32:54+00:00 weekly 0.7 https://trial.medpath.com/news/springworks-therapeutics-reports-third-quarter-2024-globenewswire 2024-11-12T17:32:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/springworks-therapeutics-reports-third-quarter-2024-globenewswire 2024-11-12T17:32:50+00:00 weekly 0.7 https://trial.medpath.com/news/abbisko-s-pimicotinib-hits-primary-endpoint-in-phase-3-tgct-trial 2024-11-12T17:31:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbisko-s-pimicotinib-hits-primary-endpoint-in-phase-3-tgct-trial 2024-11-12T17:31:50+00:00 weekly 0.7 https://trial.medpath.com/news/eu-crunch-time-for-kizfizo-sipavibart-coacillium-eight-other-products 2024-11-12T17:31:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-crunch-time-for-kizfizo-sipavibart-coacillium-eight-other-products 2024-11-12T17:31:43+00:00 weekly 0.7 https://trial.medpath.com/news/qnrx-international-sites-participating-in-qrx003-ns-study-zacks-small-cap-research 2024-11-12T17:28:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/qnrx-international-sites-participating-in-qrx003-ns-study-zacks-small-cap-research 2024-11-12T17:28:34+00:00 weekly 0.7 https://trial.medpath.com/news/23andme-cuts-40-of-its-workforce-and-discontinues-therapeutics-division-abc-news 2024-11-12T17:28:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/23andme-cuts-40-of-its-workforce-and-discontinues-therapeutics-division-abc-news 2024-11-12T17:28:22+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-s-ottava-surgical-robot-to-begin-clinical-trial-after-fda-nod-medtech-dive 2024-11-12T17:27:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-s-ottava-surgical-robot-to-begin-clinical-trial-after-fda-nod-medtech-dive 2024-11-12T17:27:59+00:00 weekly 0.7 https://trial.medpath.com/news/pimicotinib-meets-orr-end-point-in-tenosynovial-giant-cell-tumor-onclive 2024-11-12T17:19:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pimicotinib-meets-orr-end-point-in-tenosynovial-giant-cell-tumor-onclive 2024-11-12T17:19:45+00:00 weekly 0.7 https://trial.medpath.com/news/a-framework-for-n-of-1-trials-of-individualized-gene-targeted-therapies-for-genetic-diseases 2024-11-12T17:18:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-framework-for-n-of-1-trials-of-individualized-gene-targeted-therapies-for-genetic-diseases 2024-11-12T17:18:36+00:00 weekly 0.7 https://trial.medpath.com/news/neurogene-hits-a-setback-in-the-clinic-days-after-fundraise-biopharma-dive 2024-11-12T17:16:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurogene-hits-a-setback-in-the-clinic-days-after-fundraise-biopharma-dive 2024-11-12T17:16:58+00:00 weekly 0.7 https://trial.medpath.com/news/medidata-and-bioforum-bolster-decade-long-relationship-to-advance-clinical-data-and 2024-11-12T17:16:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medidata-and-bioforum-bolster-decade-long-relationship-to-advance-clinical-data-and 2024-11-12T17:16:41+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-novavax-to-resume-trials-of-covid-19-and-flu-combo-vaccine 2024-11-12T17:14:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-novavax-to-resume-trials-of-covid-19-and-flu-combo-vaccine 2024-11-12T17:14:01+00:00 weekly 0.7 https://trial.medpath.com/news/entinostat-in-combination-with-nivolumab-in-metastatic-pancreatic-ductal-adenocarcinoma 2024-11-12T17:11:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/entinostat-in-combination-with-nivolumab-in-metastatic-pancreatic-ductal-adenocarcinoma 2024-11-12T17:11:29+00:00 weekly 0.7 https://trial.medpath.com/news/uf-health-study-to-assess-pharmacogenetic-testing-in-the-er 2024-11-12T17:07:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uf-health-study-to-assess-pharmacogenetic-testing-in-the-er 2024-11-12T17:07:14+00:00 weekly 0.7 https://trial.medpath.com/news/immuno-cure-biotech-presents-promising-results-on-phase-i-clinical-trial-of-a-therapeutic 2024-11-12T17:05:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immuno-cure-biotech-presents-promising-results-on-phase-i-clinical-trial-of-a-therapeutic 2024-11-12T17:05:05+00:00 weekly 0.7 https://trial.medpath.com/news/casting-a-wide-net-when-is-the-optimal-time-for-177lu-dotatate-treatment 2024-11-12T17:02:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/casting-a-wide-net-when-is-the-optimal-time-for-177lu-dotatate-treatment 2024-11-12T17:02:35+00:00 weekly 0.7 https://trial.medpath.com/news/fda-receives-new-bla-for-dato-dxd-in-advanced-egfr-nsclc-cancer-network 2024-11-12T17:02:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-receives-new-bla-for-dato-dxd-in-advanced-egfr-nsclc-cancer-network 2024-11-12T17:02:34+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-bla-resubmission-for-epidermolysis-bullosa-gene-therapy-drug-topics 2024-11-12T16:52:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-bla-resubmission-for-epidermolysis-bullosa-gene-therapy-drug-topics 2024-11-12T16:52:38+00:00 weekly 0.7 https://trial.medpath.com/news/biotech-investors-including-third-rock-pump-100m-into-a-startup-s-genetic-medicine-for-als 2024-11-12T16:51:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biotech-investors-including-third-rock-pump-100m-into-a-startup-s-genetic-medicine-for-als 2024-11-12T16:51:53+00:00 weekly 0.7 https://trial.medpath.com/news/boston-scientific-resumes-pfa-trial-in-new-patient-group-after-pausing-enrollment 2024-11-12T16:45:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boston-scientific-resumes-pfa-trial-in-new-patient-group-after-pausing-enrollment 2024-11-12T16:45:56+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-nipocalimab-for-sjogren-s-disease-healio 2024-11-12T16:39:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-nipocalimab-for-sjogren-s-disease-healio 2024-11-12T16:39:41+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-new-drug-application-for-donidalorsen-healio 2024-11-12T16:34:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-new-drug-application-for-donidalorsen-healio 2024-11-12T16:34:05+00:00 weekly 0.7 https://trial.medpath.com/news/dmts-are-major-clinical-research-focus-for-parkinson-s-disease-analysis-shows 2024-11-12T16:33:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dmts-are-major-clinical-research-focus-for-parkinson-s-disease-analysis-shows 2024-11-12T16:33:50+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-daiichi-revise-approval-plans-for-enhertu-successor-biopharma-dive 2024-11-12T16:26:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-daiichi-revise-approval-plans-for-enhertu-successor-biopharma-dive 2024-11-12T16:26:24+00:00 weekly 0.7 https://trial.medpath.com/news/sareum-holdings-edison-vox-markets 2024-11-12T16:20:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sareum-holdings-edison-vox-markets 2024-11-12T16:20:07+00:00 weekly 0.7 https://trial.medpath.com/news/formation-bio-collaborates-with-openai-and-sanofi-to-introduce-muse-marketscreener 2024-11-12T16:16:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/formation-bio-collaborates-with-openai-and-sanofi-to-introduce-muse-marketscreener 2024-11-12T16:16:57+00:00 weekly 0.7 https://trial.medpath.com/news/one-genomic-test-can-diagnose-nearly-any-infection-uc-san-francisco 2024-11-12T16:04:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/one-genomic-test-can-diagnose-nearly-any-infection-uc-san-francisco 2024-11-12T16:04:43+00:00 weekly 0.7 https://trial.medpath.com/news/peta-the-oncostory-that-started-when-he-was-four-months-old-the-university-hospital-brno 2024-11-12T15:59:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/peta-the-oncostory-that-started-when-he-was-four-months-old-the-university-hospital-brno 2024-11-12T15:59:40+00:00 weekly 0.7 https://trial.medpath.com/news/medidata-and-bioforum-bolster-decade-long-relationship-to-advance-clinical-data-and 2024-11-12T15:57:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medidata-and-bioforum-bolster-decade-long-relationship-to-advance-clinical-data-and 2024-11-12T15:57:18+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-fda-green-light-for-robotic-system-trial-marketscreener 2024-11-12T15:56:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-fda-green-light-for-robotic-system-trial-marketscreener 2024-11-12T15:56:27+00:00 weekly 0.7 https://trial.medpath.com/news/nevro-wins-ce-mark-for-hfx-iq-spinal-cord-stim-for-pain-relief-massdevice 2024-11-12T15:53:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nevro-wins-ce-mark-for-hfx-iq-spinal-cord-stim-for-pain-relief-massdevice 2024-11-12T15:53:18+00:00 weekly 0.7 https://trial.medpath.com/news/magstim-earns-fda-clearance-for-transcranial-magnetic-stimulation-that-treats-depression-ocd 2024-11-12T15:53:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/magstim-earns-fda-clearance-for-transcranial-magnetic-stimulation-that-treats-depression-ocd 2024-11-12T15:53:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-removes-clinical-hold-on-novavax-s-covid-19-influenza-combo-vaccine 2024-11-12T15:37:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-removes-clinical-hold-on-novavax-s-covid-19-influenza-combo-vaccine 2024-11-12T15:37:30+00:00 weekly 0.7 https://trial.medpath.com/news/merck-drug-for-rare-tumour-hits-phase-3-target-pharmaphorum 2024-11-12T15:35:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-drug-for-rare-tumour-hits-phase-3-target-pharmaphorum 2024-11-12T15:35:07+00:00 weekly 0.7 https://trial.medpath.com/news/how-pfizer-used-wearables-to-tap-into-the-promise-of-an-experimental-drug-stat-news 2024-11-12T15:31:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-pfizer-used-wearables-to-tap-into-the-promise-of-an-experimental-drug-stat-news 2024-11-12T15:31:41+00:00 weekly 0.7 https://trial.medpath.com/news/first-line-triplet-therapy-for-advanced-stage-pik3ca-mutant-hr-breast-cancer-improves-outcomes 2024-11-12T15:25:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-line-triplet-therapy-for-advanced-stage-pik3ca-mutant-hr-breast-cancer-improves-outcomes 2024-11-12T15:25:00+00:00 weekly 0.7 https://trial.medpath.com/news/buy-sell-or-hold-bmy-stock-forbes 2024-11-12T15:22:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/buy-sell-or-hold-bmy-stock-forbes 2024-11-12T15:22:57+00:00 weekly 0.7 https://trial.medpath.com/news/antelope-surgical-solutions-achieves-commercial-investigational-new-drug-ind-approval 2024-11-12T15:20:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/antelope-surgical-solutions-achieves-commercial-investigational-new-drug-ind-approval 2024-11-12T15:20:55+00:00 weekly 0.7 https://trial.medpath.com/news/springworks-therapeutics-inc-sec-10-q-report-tradingview 2024-11-12T15:16:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/springworks-therapeutics-inc-sec-10-q-report-tradingview 2024-11-12T15:16:00+00:00 weekly 0.7 https://trial.medpath.com/news/prominent-usc-scientist-goes-on-leave-amid-research-misconduct-allegations-national 2024-11-12T15:14:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prominent-usc-scientist-goes-on-leave-amid-research-misconduct-allegations-national 2024-11-12T15:14:38+00:00 weekly 0.7 https://trial.medpath.com/news/antelope-surgical-solutions-achieves-commercial-investigational-new-drug-ind-approval 2024-11-12T15:13:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/antelope-surgical-solutions-achieves-commercial-investigational-new-drug-ind-approval 2024-11-12T15:13:35+00:00 weekly 0.7 https://trial.medpath.com/news/zolbetuximab-plus-chemotherapy-offers-survival-benefits-in-treatment-naive-her2-onclive 2024-11-12T15:10:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zolbetuximab-plus-chemotherapy-offers-survival-benefits-in-treatment-naive-her2-onclive 2024-11-12T15:10:25+00:00 weekly 0.7 https://trial.medpath.com/news/arch-biopartners-doses-first-subject-in-trial-of-acute-kidney-injury-treatment 2024-11-12T15:04:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arch-biopartners-doses-first-subject-in-trial-of-acute-kidney-injury-treatment 2024-11-12T15:04:17+00:00 weekly 0.7 https://trial.medpath.com/news/multimodal-scanning-of-genetic-variants-with-base-and-prime-editing-nature-biotechnology 2024-11-12T15:03:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/multimodal-scanning-of-genetic-variants-with-base-and-prime-editing-nature-biotechnology 2024-11-12T15:03:00+00:00 weekly 0.7 https://trial.medpath.com/news/seattle-children-s-now-enrolling-participants-for-first-u-s-car-t-cell-clinical-trial-for 2024-11-12T14:54:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/seattle-children-s-now-enrolling-participants-for-first-u-s-car-t-cell-clinical-trial-for 2024-11-12T14:54:36+00:00 weekly 0.7 https://trial.medpath.com/news/ema-s-final-call-on-alzheimer-s-drug-leqembi-imminent-citeline 2024-11-12T14:53:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-s-final-call-on-alzheimer-s-drug-leqembi-imminent-citeline 2024-11-12T14:53:33+00:00 weekly 0.7 https://trial.medpath.com/news/quantalx-secures-fda-clearance-for-its-breakthrough-delphi-stimulator-advancing-direct 2024-11-12T14:41:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/quantalx-secures-fda-clearance-for-its-breakthrough-delphi-stimulator-advancing-direct 2024-11-12T14:41:33+00:00 weekly 0.7 https://trial.medpath.com/news/after-decades-of-work-an-atypical-schizophrenia-drug-is-approved 2024-11-12T14:38:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/after-decades-of-work-an-atypical-schizophrenia-drug-is-approved 2024-11-12T14:38:01+00:00 weekly 0.7 https://trial.medpath.com/news/refined-definition-of-platinum-resistance-novel-adcs-could-brind-more-changes-to-onclive 2024-11-12T14:30:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/refined-definition-of-platinum-resistance-novel-adcs-could-brind-more-changes-to-onclive 2024-11-12T14:30:01+00:00 weekly 0.7 https://trial.medpath.com/news/komet-phase-iii-trial-met-primary-endpoint-shares-magazine 2024-11-12T14:22:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/komet-phase-iii-trial-met-primary-endpoint-shares-magazine 2024-11-12T14:22:23+00:00 weekly 0.7 https://trial.medpath.com/news/summary-report-on-authorisation-givlaari-r-swissmedic 2024-11-12T14:20:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/summary-report-on-authorisation-givlaari-r-swissmedic 2024-11-12T14:20:55+00:00 weekly 0.7 https://trial.medpath.com/news/fda-issues-crl-to-obeticholic-acid-ocaliva-denies-full-approval-for-pbc-hcplive 2024-11-12T14:19:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-issues-crl-to-obeticholic-acid-ocaliva-denies-full-approval-for-pbc-hcplive 2024-11-12T14:19:05+00:00 weekly 0.7 https://trial.medpath.com/news/cadrenal-therapeutics-highlights-presentation-at-european-yahoo-finance 2024-11-12T14:17:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cadrenal-therapeutics-highlights-presentation-at-european-yahoo-finance 2024-11-12T14:17:43+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-disappointing-schizophrenia-drug-trial-bodes-well-for-rival-bristol-myers-analysts-say 2024-11-12T14:16:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-s-disappointing-schizophrenia-drug-trial-bodes-well-for-rival-bristol-myers-analysts-say 2024-11-12T14:16:26+00:00 weekly 0.7 https://trial.medpath.com/news/cadrenal-s-tecarfarin-shows-promise-for-lvad-patients-in-key-medical-congress-data 2024-11-12T14:09:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cadrenal-s-tecarfarin-shows-promise-for-lvad-patients-in-key-medical-congress-data 2024-11-12T14:09:16+00:00 weekly 0.7 https://trial.medpath.com/news/woolsey-pharmaceuticals-completes-patient-recruitment-for-high-dose-cohort-of-als-study 2024-11-12T14:05:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/woolsey-pharmaceuticals-completes-patient-recruitment-for-high-dose-cohort-of-als-study 2024-11-12T14:05:46+00:00 weekly 0.7 https://trial.medpath.com/news/cadrenal-therapeutics-highlights-presentation-at-european-placera 2024-11-12T14:05:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cadrenal-therapeutics-highlights-presentation-at-european-placera 2024-11-12T14:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/longboard-pharmaceuticals-initiates-phase-3-deep-ocean-study-evaluating-bexicaserin 2024-11-12T13:58:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/longboard-pharmaceuticals-initiates-phase-3-deep-ocean-study-evaluating-bexicaserin 2024-11-12T13:58:28+00:00 weekly 0.7 https://trial.medpath.com/news/aurobindo-unit-gets-ema-nod-for-biosimilar-facility-the-week 2024-11-12T13:29:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aurobindo-unit-gets-ema-nod-for-biosimilar-facility-the-week 2024-11-12T13:29:54+00:00 weekly 0.7 https://trial.medpath.com/news/caliway-announced-ema-orphan-drug-designation-granted-to-cbl-514-for-dercum-s 2024-11-12T13:29:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/caliway-announced-ema-orphan-drug-designation-granted-to-cbl-514-for-dercum-s 2024-11-12T13:29:01+00:00 weekly 0.7 https://trial.medpath.com/news/caliway-announced-ema-orphan-drug-designation-granted-to-cbl-514-for-dercum-s 2024-11-12T13:28:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/caliway-announced-ema-orphan-drug-designation-granted-to-cbl-514-for-dercum-s 2024-11-12T13:28:17+00:00 weekly 0.7 https://trial.medpath.com/news/tonix-pharmaceuticals-reports-third-quarter-2024-financial-globenewswire 2024-11-12T13:27:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tonix-pharmaceuticals-reports-third-quarter-2024-financial-globenewswire 2024-11-12T13:27:03+00:00 weekly 0.7 https://trial.medpath.com/news/glyconex-announces-manufacturing-agreement-with-sterling-for-gnx102-adc-clinical-trial 2024-11-12T13:26:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glyconex-announces-manufacturing-agreement-with-sterling-for-gnx102-adc-clinical-trial 2024-11-12T13:26:12+00:00 weekly 0.7 https://trial.medpath.com/news/acuitive-technologies-receives-fda-510-k-clearance-for-globenewswire 2024-11-12T13:24:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acuitive-technologies-receives-fda-510-k-clearance-for-globenewswire 2024-11-12T13:24:28+00:00 weekly 0.7 https://trial.medpath.com/news/icad-s-profound-detection-version-4-0-gains-fda-clearance-globenewswire 2024-11-12T13:23:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/icad-s-profound-detection-version-4-0-gains-fda-clearance-globenewswire 2024-11-12T13:23:48+00:00 weekly 0.7 https://trial.medpath.com/news/savara-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-12T13:23:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/savara-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-12T13:23:02+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-submits-eu-and-us-applications-for-subcutaneous-darzalex-in-smouldering-multiple-myeloma 2024-11-12T13:17:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-submits-eu-and-us-applications-for-subcutaneous-darzalex-in-smouldering-multiple-myeloma 2024-11-12T13:17:11+00:00 weekly 0.7 https://trial.medpath.com/news/enlivex-announces-the-enrollment-and-dosing-of-the-first-10-patient-in-the-randomized 2024-11-12T13:17:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enlivex-announces-the-enrollment-and-dosing-of-the-first-10-patient-in-the-randomized 2024-11-12T13:17:04+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-stock-plummets-over-12-after-schizophrenia-drug-flops-in-phase-ii-trials 2024-11-12T13:17:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-s-stock-plummets-over-12-after-schizophrenia-drug-flops-in-phase-ii-trials 2024-11-12T13:17:02+00:00 weekly 0.7 https://trial.medpath.com/news/moleculin-s-breakthrough-fda-fast-track-cancer-drug-advances-to-pivotal-phase-3-trial 2024-11-12T13:11:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moleculin-s-breakthrough-fda-fast-track-cancer-drug-advances-to-pivotal-phase-3-trial 2024-11-12T13:11:17+00:00 weekly 0.7 https://trial.medpath.com/news/enlivex-s-allocetra-advances-phase-ii-trial-launches-for-knee-osteoarthritis-treatment 2024-11-12T13:11:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enlivex-s-allocetra-advances-phase-ii-trial-launches-for-knee-osteoarthritis-treatment 2024-11-12T13:11:09+00:00 weekly 0.7 https://trial.medpath.com/news/moleculin-receives-institutional-review-board-approval-for-miracle-phase-3-pivotal-trial 2024-11-12T13:08:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moleculin-receives-institutional-review-board-approval-for-miracle-phase-3-pivotal-trial 2024-11-12T13:08:04+00:00 weekly 0.7 https://trial.medpath.com/news/tonix-pharmaceuticals-reports-third-quarter-2024-financial-results-and-operational-highlights 2024-11-12T13:06:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tonix-pharmaceuticals-reports-third-quarter-2024-financial-results-and-operational-highlights 2024-11-12T13:06:56+00:00 weekly 0.7 https://trial.medpath.com/news/ascletis-completes-enrollment-of-phase-iii-trial-of-asc40-denifanstat-once-daily-oral 2024-11-12T13:04:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ascletis-completes-enrollment-of-phase-iii-trial-of-asc40-denifanstat-once-daily-oral 2024-11-12T13:04:34+00:00 weekly 0.7 https://trial.medpath.com/news/ascletis-completes-enrollment-of-phase-iii-trial-of-asc40-denifanstat-once-daily-oral 2024-11-12T12:52:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ascletis-completes-enrollment-of-phase-iii-trial-of-asc40-denifanstat-once-daily-oral 2024-11-12T12:52:09+00:00 weekly 0.7 https://trial.medpath.com/news/genascence-granted-fda-fast-track-designation-for-gnsc-001-in-patients-with-pr-newswire 2024-11-12T12:51:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genascence-granted-fda-fast-track-designation-for-gnsc-001-in-patients-with-pr-newswire 2024-11-12T12:51:41+00:00 weekly 0.7 https://trial.medpath.com/news/wave-life-sciences-reports-third-quarter-2024-financial-globenewswire 2024-11-12T12:44:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wave-life-sciences-reports-third-quarter-2024-financial-globenewswire 2024-11-12T12:44:07+00:00 weekly 0.7 https://trial.medpath.com/news/novavax-announces-fda-clinical-hold-lift-on-phase-3-covid-19-flu-vaccine-study-pmlive 2024-11-12T12:41:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novavax-announces-fda-clinical-hold-lift-on-phase-3-covid-19-flu-vaccine-study-pmlive 2024-11-12T12:41:24+00:00 weekly 0.7 https://trial.medpath.com/news/glyconex-announces-manufacturing-agreement-with-sterling-for-gnx102-adc-clinical-trial 2024-11-12T12:37:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glyconex-announces-manufacturing-agreement-with-sterling-for-gnx102-adc-clinical-trial 2024-11-12T12:37:41+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-pharma-reports-third-quarter-2024-financial-results-and-business-update 2024-11-12T12:34:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bridgebio-pharma-reports-third-quarter-2024-financial-results-and-business-update 2024-11-12T12:34:20+00:00 weekly 0.7 https://trial.medpath.com/news/spyre-s-ibd-drug-shows-breakthrough-90-day-half-life-in-phase-1-trial-4x-better-than-standard 2024-11-12T12:34:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spyre-s-ibd-drug-shows-breakthrough-90-day-half-life-in-phase-1-trial-4x-better-than-standard 2024-11-12T12:34:13+00:00 weekly 0.7 https://trial.medpath.com/news/abeona-therapeutics-r-announces-fda-acceptance-of-bla-globenewswire 2024-11-12T12:33:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abeona-therapeutics-r-announces-fda-acceptance-of-bla-globenewswire 2024-11-12T12:33:54+00:00 weekly 0.7 https://trial.medpath.com/news/mereo-biopharma-reports-third-quarter-2024-financial-globenewswire 2024-11-12T12:33:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mereo-biopharma-reports-third-quarter-2024-financial-globenewswire 2024-11-12T12:33:34+00:00 weekly 0.7 https://trial.medpath.com/news/momentis-surgical-gets-fda-approval-for-second-generation-anovo-robotic-platform 2024-11-12T12:29:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/momentis-surgical-gets-fda-approval-for-second-generation-anovo-robotic-platform 2024-11-12T12:29:12+00:00 weekly 0.7 https://trial.medpath.com/news/ascletis-completes-enrollment-of-phase-iii-trial-of-asc40-denifanstat-once-daily-oral 2024-11-12T12:26:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ascletis-completes-enrollment-of-phase-iii-trial-of-asc40-denifanstat-once-daily-oral 2024-11-12T12:26:43+00:00 weekly 0.7 https://trial.medpath.com/news/exostat-medical-receives-fda-clearance-for-novel-real-time-oral-tissue-perfusion 2024-11-12T12:24:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exostat-medical-receives-fda-clearance-for-novel-real-time-oral-tissue-perfusion 2024-11-12T12:24:47+00:00 weekly 0.7 https://trial.medpath.com/news/multiomic-health-announces-discovery-of-novel-endotypes-and-biomarkers-for-diabetic 2024-11-12T12:23:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/multiomic-health-announces-discovery-of-novel-endotypes-and-biomarkers-for-diabetic 2024-11-12T12:23:55+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-stock-plummets-over-12-after-schizophrenia-drug-flops-in-phase-ii-trials 2024-11-12T12:18:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-s-stock-plummets-over-12-after-schizophrenia-drug-flops-in-phase-ii-trials 2024-11-12T12:18:09+00:00 weekly 0.7 https://trial.medpath.com/news/chinese-regulator-raises-red-flag-on-clinical-trial-bribery-citeline 2024-11-12T12:17:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chinese-regulator-raises-red-flag-on-clinical-trial-bribery-citeline 2024-11-12T12:17:23+00:00 weekly 0.7 https://trial.medpath.com/news/iteos-reports-third-quarter-2024-financial-results-and-provides-business-updates 2024-11-12T12:16:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iteos-reports-third-quarter-2024-financial-results-and-provides-business-updates 2024-11-12T12:16:46+00:00 weekly 0.7 https://trial.medpath.com/news/zenas-biopharma-hits-milestone-completes-enrollment-in-largest-ever-igg4-rd-trial 2024-11-12T12:13:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zenas-biopharma-hits-milestone-completes-enrollment-in-largest-ever-igg4-rd-trial 2024-11-12T12:13:22+00:00 weekly 0.7 https://trial.medpath.com/news/nomic-r-and-parker-institute-for-cancer-immunotherapy-pici-launch-large-scale-news-medical 2024-11-12T12:12:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nomic-r-and-parker-institute-for-cancer-immunotherapy-pici-launch-large-scale-news-medical 2024-11-12T12:12:48+00:00 weekly 0.7 https://trial.medpath.com/news/avadel-pharmaceuticals-provides-corporate-update-and-globenewswire 2024-11-12T12:10:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avadel-pharmaceuticals-provides-corporate-update-and-globenewswire 2024-11-12T12:10:07+00:00 weekly 0.7 https://trial.medpath.com/news/oncolytics-biotech-r-reports-third-quarter-2024-financial-results-and-operational-highlights 2024-11-12T12:09:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oncolytics-biotech-r-reports-third-quarter-2024-financial-results-and-operational-highlights 2024-11-12T12:09:20+00:00 weekly 0.7 https://trial.medpath.com/news/autolus-therapeutics-reports-third-quarter-2024-financial-results-and-business-updates 2024-11-12T12:07:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/autolus-therapeutics-reports-third-quarter-2024-financial-results-and-business-updates 2024-11-12T12:07:44+00:00 weekly 0.7 https://trial.medpath.com/news/bioxcel-therapeutics-advances-pivotal-phase-3-trials-of-globenewswire 2024-11-12T12:06:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bioxcel-therapeutics-advances-pivotal-phase-3-trials-of-globenewswire 2024-11-12T12:06:12+00:00 weekly 0.7 https://trial.medpath.com/news/axsome-therapeutics-reports-third-quarter-2024-financial-globenewswire 2024-11-12T12:05:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/axsome-therapeutics-reports-third-quarter-2024-financial-globenewswire 2024-11-12T12:05:11+00:00 weekly 0.7 https://trial.medpath.com/news/autolus-therapeutics-reports-third-quarter-2024-financial-results-and-business-updates 2024-11-12T12:05:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/autolus-therapeutics-reports-third-quarter-2024-financial-results-and-business-updates 2024-11-12T12:05:03+00:00 weekly 0.7 https://trial.medpath.com/news/formation-bio-collaborates-with-sanofi-and-openai-to-introduce-muse-a-first-of-its-kind-ai 2024-11-12T12:03:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/formation-bio-collaborates-with-sanofi-and-openai-to-introduce-muse-a-first-of-its-kind-ai 2024-11-12T12:03:35+00:00 weekly 0.7 https://trial.medpath.com/news/belite-bio-reports-third-quarter-2024-financial-results-and-provides-a-corporate-update 2024-11-12T12:02:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/belite-bio-reports-third-quarter-2024-financial-results-and-provides-a-corporate-update 2024-11-12T12:02:42+00:00 weekly 0.7 https://trial.medpath.com/news/datopotamab-deruxtecan-new-bla-submitted-for-accelerated-approval-in-the-us-for-patients 2024-11-12T12:02:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/datopotamab-deruxtecan-new-bla-submitted-for-accelerated-approval-in-the-us-for-patients 2024-11-12T12:02:32+00:00 weekly 0.7 https://trial.medpath.com/news/zai-lab-announces-third-quarter-2024-financial-results-and-recent-corporate-updates 2024-11-12T11:58:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zai-lab-announces-third-quarter-2024-financial-results-and-recent-corporate-updates 2024-11-12T11:58:42+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-daiichi-sankyo-change-strategy-on-closely-watched-cancer-drug-stat-news 2024-11-12T11:58:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-daiichi-sankyo-change-strategy-on-closely-watched-cancer-drug-stat-news 2024-11-12T11:58:04+00:00 weekly 0.7 https://trial.medpath.com/news/show-chwan-health-care-system-joins-novotech-to-accelerate-the-quality-of-clinical-leader 2024-11-12T11:52:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/show-chwan-health-care-system-joins-novotech-to-accelerate-the-quality-of-clinical-leader 2024-11-12T11:52:03+00:00 weekly 0.7 https://trial.medpath.com/news/koselugo-r-selumetinib-showed-significant-and-clinically-meaningful-improvement-in 2024-11-12T11:50:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/koselugo-r-selumetinib-showed-significant-and-clinically-meaningful-improvement-in 2024-11-12T11:50:10+00:00 weekly 0.7 https://trial.medpath.com/news/ascletis-completes-phase-3-enrollment-for-novel-acne-drug-building-on-phase-2-success 2024-11-12T11:40:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ascletis-completes-phase-3-enrollment-for-novel-acne-drug-building-on-phase-2-success 2024-11-12T11:40:36+00:00 weekly 0.7 https://trial.medpath.com/news/ascletis-completes-enrollment-of-phase-iii-trial-of-asc40-denifanstat-once-daily-oral 2024-11-12T11:33:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ascletis-completes-enrollment-of-phase-iii-trial-of-asc40-denifanstat-once-daily-oral 2024-11-12T11:33:34+00:00 weekly 0.7 https://trial.medpath.com/news/viiv-healthcare-shares-results-from-trial-of-dovato-and-three-drug-therapy-for-hiv 2024-11-12T11:33:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/viiv-healthcare-shares-results-from-trial-of-dovato-and-three-drug-therapy-for-hiv 2024-11-12T11:33:07+00:00 weekly 0.7 https://trial.medpath.com/news/arrowhead-pharmaceuticals-launches-awareness-campaign-for-fcs 2024-11-12T11:04:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arrowhead-pharmaceuticals-launches-awareness-campaign-for-fcs 2024-11-12T11:04:51+00:00 weekly 0.7 https://trial.medpath.com/news/rowan-based-startup-receives-fda-clearance-for-medical-technology 2024-11-12T11:02:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rowan-based-startup-receives-fda-clearance-for-medical-technology 2024-11-12T11:02:49+00:00 weekly 0.7 https://trial.medpath.com/news/scientific-leadership-spotlighted-as-gilead-presents-research-data-across-its-broad-and 2024-11-12T10:45:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scientific-leadership-spotlighted-as-gilead-presents-research-data-across-its-broad-and 2024-11-12T10:45:47+00:00 weekly 0.7 https://trial.medpath.com/news/lipella-pharmaceuticals-secures-extended-market-exclusivity-globenewswire 2024-11-12T10:32:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lipella-pharmaceuticals-secures-extended-market-exclusivity-globenewswire 2024-11-12T10:32:25+00:00 weekly 0.7 https://trial.medpath.com/news/syncona-proud-but-not-revived-by-autolus-winning-fda-approval-citywire 2024-11-12T10:26:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syncona-proud-but-not-revived-by-autolus-winning-fda-approval-citywire 2024-11-12T10:26:11+00:00 weekly 0.7 https://trial.medpath.com/news/autolus-car-t-aucatzyl-wins-us-fda-nod-for-leukemia-bioworld 2024-11-12T10:09:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/autolus-car-t-aucatzyl-wins-us-fda-nod-for-leukemia-bioworld 2024-11-12T10:09:10+00:00 weekly 0.7 https://trial.medpath.com/news/revolutionising-heart-health-frontier-x-plus-gains-fda-approval-aw-athletics-weekly 2024-11-12T10:04:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/revolutionising-heart-health-frontier-x-plus-gains-fda-approval-aw-athletics-weekly 2024-11-12T10:04:29+00:00 weekly 0.7 https://trial.medpath.com/news/merck-kgaa-phase-iii-trial-of-pimicotinib-in-tenosynovial-giant-cell-tumor-meets-primary-endpoint 2024-11-12T09:53:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-kgaa-phase-iii-trial-of-pimicotinib-in-tenosynovial-giant-cell-tumor-meets-primary-endpoint 2024-11-12T09:53:17+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-status-to-j-j-s-nipocalimab-for-sjd-treatment 2024-11-12T09:34:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-breakthrough-status-to-j-j-s-nipocalimab-for-sjd-treatment 2024-11-12T09:34:56+00:00 weekly 0.7 https://trial.medpath.com/news/astra-invests-3-5-billion-in-us-as-cancer-drug-lifts-sales-bnn-bloomberg 2024-11-12T09:34:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astra-invests-3-5-billion-in-us-as-cancer-drug-lifts-sales-bnn-bloomberg 2024-11-12T09:34:11+00:00 weekly 0.7 https://trial.medpath.com/news/merck-kgaa-phase-iii-trial-of-pimicotinib-in-tenosynovial-giant-cell-tumor-meets-primary-endpoint 2024-11-12T09:07:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-kgaa-phase-iii-trial-of-pimicotinib-in-tenosynovial-giant-cell-tumor-meets-primary-endpoint 2024-11-12T09:07:59+00:00 weekly 0.7 https://trial.medpath.com/news/nipocalimab-gets-fda-breakthrough-status-tradingview 2024-11-12T08:49:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nipocalimab-gets-fda-breakthrough-status-tradingview 2024-11-12T08:49:30+00:00 weekly 0.7 https://trial.medpath.com/news/tdf-litigation-gilead-sciences 2024-11-12T08:40:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tdf-litigation-gilead-sciences 2024-11-12T08:40:24+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-koselugo-phase-iii-trial-meets-primary-goal-in-adults-with-neurofibromatosis-type-1 2024-11-12T08:29:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-koselugo-phase-iii-trial-meets-primary-goal-in-adults-with-neurofibromatosis-type-1 2024-11-12T08:29:46+00:00 weekly 0.7 https://trial.medpath.com/news/nanobiotix-provides-third-quarter-2024-update-and-progress-on-nanotherapeutics-platforms 2024-11-12T07:50:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nanobiotix-provides-third-quarter-2024-update-and-progress-on-nanotherapeutics-platforms 2024-11-12T07:50:33+00:00 weekly 0.7 https://trial.medpath.com/news/koselugo-showed-statistically-significant-and-clinically-meaningful-objective-response-rate 2024-11-12T07:06:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/koselugo-showed-statistically-significant-and-clinically-meaningful-objective-response-rate 2024-11-12T07:06:37+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-announces-u-s-food-and-drug-administration-grants-nipocalimab 2024-11-12T07:01:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-announces-u-s-food-and-drug-administration-grants-nipocalimab 2024-11-12T07:01:02+00:00 weekly 0.7 https://trial.medpath.com/news/belite-bio-reports-third-quarter-2024-financial-results-and-provides-a-corporate-update 2024-11-12T06:38:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/belite-bio-reports-third-quarter-2024-financial-results-and-provides-a-corporate-update 2024-11-12T06:38:10+00:00 weekly 0.7 https://trial.medpath.com/news/relacorilant-plus-nab-paclitaxel-carves-new-avenues-of-platinum-resistant-ovarian-cancer-care 2024-11-12T06:33:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/relacorilant-plus-nab-paclitaxel-carves-new-avenues-of-platinum-resistant-ovarian-cancer-care 2024-11-12T06:33:33+00:00 weekly 0.7 https://trial.medpath.com/news/pimicotinib-significantly-improved-outcomes-for-patients-with-tenosynovial-giant-cell 2024-11-12T06:21:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pimicotinib-significantly-improved-outcomes-for-patients-with-tenosynovial-giant-cell 2024-11-12T06:21:56+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-analysis-shows-tafinlar-plus-mekinist-reduces-mortality-risk-in-stage-iii-melanoma 2024-11-12T06:17:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/long-term-analysis-shows-tafinlar-plus-mekinist-reduces-mortality-risk-in-stage-iii-melanoma 2024-11-12T06:17:59+00:00 weekly 0.7 https://trial.medpath.com/news/optimizing-clinical-trial-efficiency-the-power-of-simplicity-for-first-in-human-studies 2024-11-12T06:17:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/optimizing-clinical-trial-efficiency-the-power-of-simplicity-for-first-in-human-studies 2024-11-12T06:17:58+00:00 weekly 0.7 https://trial.medpath.com/news/kancera-focuses-on-cardiovascular-diseases-placera 2024-11-12T06:04:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kancera-focuses-on-cardiovascular-diseases-placera 2024-11-12T06:04:49+00:00 weekly 0.7 https://trial.medpath.com/news/early-treatment-of-hepatitis-b-is-key-to-preventing-liver-cancer-and-reducing-healthcare-costs 2024-11-12T05:50:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/early-treatment-of-hepatitis-b-is-key-to-preventing-liver-cancer-and-reducing-healthcare-costs 2024-11-12T05:50:45+00:00 weekly 0.7 https://trial.medpath.com/news/phase-i-clinical-trial-of-pembrolizumab-and-denileukin-diftitox-in-patients-with-recurrent 2024-11-12T05:35:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-i-clinical-trial-of-pembrolizumab-and-denileukin-diftitox-in-patients-with-recurrent 2024-11-12T05:35:34+00:00 weekly 0.7 https://trial.medpath.com/news/organogenesis-phase-3-trial-success-renu-knee-treatment-shows-promising-results 2024-11-12T05:05:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/organogenesis-phase-3-trial-success-renu-knee-treatment-shows-promising-results 2024-11-12T05:05:25+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-submits-applications-in-the-u-s-and-eu-seeking-approval-of-marketscreener 2024-11-12T03:39:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-submits-applications-in-the-u-s-and-eu-seeking-approval-of-marketscreener 2024-11-12T03:39:53+00:00 weekly 0.7 https://trial.medpath.com/news/recordati-s-isturisa-wins-korean-approval-to-treat-cusing-s-disease-pharma-article-kbr 2024-11-12T02:37:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recordati-s-isturisa-wins-korean-approval-to-treat-cusing-s-disease-pharma-article-kbr 2024-11-12T02:37:51+00:00 weekly 0.7 https://trial.medpath.com/news/what-s-behind-the-insider-buying-on-this-high-yield-stock-the-globe-and-mail 2024-11-12T01:49:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/what-s-behind-the-insider-buying-on-this-high-yield-stock-the-globe-and-mail 2024-11-12T01:49:43+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-fda-removes-clinical-hold-on-novavax-s-covid-19-influenza-combination-and-stand 2024-11-12T00:25:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-s-fda-removes-clinical-hold-on-novavax-s-covid-19-influenza-combination-and-stand 2024-11-12T00:25:50+00:00 weekly 0.7 https://trial.medpath.com/news/chinese-regulator-raises-red-flag-on-clinical-trial-bribery 2024-11-12T00:17:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chinese-regulator-raises-red-flag-on-clinical-trial-bribery 2024-11-12T00:17:24+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-gets-breakthrough-therapy-designation-for-sjogren-s-disease-treatment 2024-11-12T00:07:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-gets-breakthrough-therapy-designation-for-sjogren-s-disease-treatment 2024-11-12T00:07:43+00:00 weekly 0.7 https://trial.medpath.com/news/allo-316-shows-50-response-rate-in-cd70-positive-rcc-in-phase-1-trial 2024-11-12T00:01:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/allo-316-shows-50-response-rate-in-cd70-positive-rcc-in-phase-1-trial 2024-11-12T00:01:14+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-gets-breakthrough-therapy-designation-for-sjogren-s-disease-treatment 2024-11-12T00:00:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-gets-breakthrough-therapy-designation-for-sjogren-s-disease-treatment 2024-11-12T00:00:16+00:00 weekly 0.7 https://trial.medpath.com/news/cogent-biosciences-reports-recent-business-highlights-and-third-quarter-2024-financial-results 2024-11-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cogent-biosciences-reports-recent-business-highlights-and-third-quarter-2024-financial-results 2024-11-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/citius-pharmaceuticals-lymphir-and-keytruda-combo-shows-promising-clinical-outcomes-earning-a-buy-rating 2024-11-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/citius-pharmaceuticals-lymphir-and-keytruda-combo-shows-promising-clinical-outcomes-earning-a-buy-rating 2024-11-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/singapore-launches-asia-s-first-mrna-biofoundry-to-advance-nucleic-acid-therapeutics 2024-11-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/singapore-launches-asia-s-first-mrna-biofoundry-to-advance-nucleic-acid-therapeutics 2024-11-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-lifts-clinical-hold-on-novavax-s-trials-for-covid-19-influenza-combination 2024-11-11T23:27:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-lifts-clinical-hold-on-novavax-s-trials-for-covid-19-influenza-combination 2024-11-11T23:27:07+00:00 weekly 0.7 https://trial.medpath.com/news/bostongene-sweeps-2024-pharmaceutical-excellence-awards-with-ai-powered-cancer-diagnostics-platform 2024-11-11T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bostongene-sweeps-2024-pharmaceutical-excellence-awards-with-ai-powered-cancer-diagnostics-platform 2024-11-11T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/value-of-abbvie-s-cerevel-buy-uncertain-after-schizophrenia-failure-citeline 2024-11-11T22:52:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/value-of-abbvie-s-cerevel-buy-uncertain-after-schizophrenia-failure-citeline 2024-11-11T22:52:05+00:00 weekly 0.7 https://trial.medpath.com/news/nk-cell-therapy-clinical-trial-pipeline-appears-robust-with-140-key-pharma-pr-newswire 2024-11-11T22:34:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nk-cell-therapy-clinical-trial-pipeline-appears-robust-with-140-key-pharma-pr-newswire 2024-11-11T22:34:55+00:00 weekly 0.7 https://trial.medpath.com/news/on-wall-street-flat-out-failure-of-abbvie-schizophrenia-drug-leaves-analysts-stunned 2024-11-11T22:30:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/on-wall-street-flat-out-failure-of-abbvie-schizophrenia-drug-leaves-analysts-stunned 2024-11-11T22:30:17+00:00 weekly 0.7 https://trial.medpath.com/news/zongertinib-a-promising-new-tki-for-her2-mutated-nsclc-pharmacy-times 2024-11-11T22:27:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zongertinib-a-promising-new-tki-for-her2-mutated-nsclc-pharmacy-times 2024-11-11T22:27:32+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-tumbles-after-new-schizophrenia-drug-fails-two-trials-yahoo-finance 2024-11-11T22:19:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-tumbles-after-new-schizophrenia-drug-fails-two-trials-yahoo-finance 2024-11-11T22:19:25+00:00 weekly 0.7 https://trial.medpath.com/news/eureka-therapeutics-tackling-advanced-hepatocellular-carcinoma-with-t-cell-therapy 2024-11-11T22:14:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eureka-therapeutics-tackling-advanced-hepatocellular-carcinoma-with-t-cell-therapy 2024-11-11T22:14:12+00:00 weekly 0.7 https://trial.medpath.com/news/aberdeen-woman-says-blood-cancer-drug-approval-could-give-her-chance-of-more-normal-life 2024-11-11T22:05:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aberdeen-woman-says-blood-cancer-drug-approval-could-give-her-chance-of-more-normal-life 2024-11-11T22:05:14+00:00 weekly 0.7 https://trial.medpath.com/news/impact-of-cable-lock-distribution-on-firearm-securement-after-emergent-mental-health-evaluation 2024-11-11T21:48:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/impact-of-cable-lock-distribution-on-firearm-securement-after-emergent-mental-health-evaluation 2024-11-11T21:48:33+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-nipocalimab-second-breakthrough-therapy-designation-investing-com 2024-11-11T21:47:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-nipocalimab-second-breakthrough-therapy-designation-investing-com 2024-11-11T21:47:57+00:00 weekly 0.7 https://trial.medpath.com/news/spyre-therapeutics-to-host-conference-call-and-webcast-to-report-interim-results-morningstar 2024-11-11T21:45:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spyre-therapeutics-to-host-conference-call-and-webcast-to-report-interim-results-morningstar 2024-11-11T21:45:55+00:00 weekly 0.7 https://trial.medpath.com/news/adding-targeted-agent-to-perioperative-therapy-for-rcc-may-improve-disease-control 2024-11-11T21:38:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adding-targeted-agent-to-perioperative-therapy-for-rcc-may-improve-disease-control 2024-11-11T21:38:42+00:00 weekly 0.7 https://trial.medpath.com/news/sonoma-pharma-secures-fda-clearance-for-enhanced-wound-care-hydrogel-technology 2024-11-11T21:37:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sonoma-pharma-secures-fda-clearance-for-enhanced-wound-care-hydrogel-technology 2024-11-11T21:37:26+00:00 weekly 0.7 https://trial.medpath.com/news/mineralys-therapeutics-reports-third-quarter-2024-financial-results-and-provides 2024-11-11T21:21:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mineralys-therapeutics-reports-third-quarter-2024-financial-results-and-provides 2024-11-11T21:21:27+00:00 weekly 0.7 https://trial.medpath.com/news/quince-therapeutics-presents-safety-data-from-prior-phase-3-attest-clinical-trial-at-53rd 2024-11-11T21:21:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/quince-therapeutics-presents-safety-data-from-prior-phase-3-attest-clinical-trial-at-53rd 2024-11-11T21:21:25+00:00 weekly 0.7 https://trial.medpath.com/news/quince-therapeutics-erydex-shows-promising-safety-data-in-phase-3-a-t-trial-qncx-stock-news 2024-11-11T21:20:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/quince-therapeutics-erydex-shows-promising-safety-data-in-phase-3-a-t-trial-qncx-stock-news 2024-11-11T21:20:54+00:00 weekly 0.7 https://trial.medpath.com/news/livanova-announces-osprey-clinical-study-meets-primary-safety-and-efficacy-endpoints 2024-11-11T21:20:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/livanova-announces-osprey-clinical-study-meets-primary-safety-and-efficacy-endpoints 2024-11-11T21:20:51+00:00 weekly 0.7 https://trial.medpath.com/news/nipocalimab-is-the-first-and-only-investigational-therapy-granted-u-s-fda-breakthrough 2024-11-11T21:08:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nipocalimab-is-the-first-and-only-investigational-therapy-granted-u-s-fda-breakthrough 2024-11-11T21:08:39+00:00 weekly 0.7 https://trial.medpath.com/news/thio-combo-shows-enduring-activity-in-advanced-non-small-cell-lung-cancer 2024-11-11T21:08:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/thio-combo-shows-enduring-activity-in-advanced-non-small-cell-lung-cancer 2024-11-11T21:08:09+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-immunotherapy-for-aggressive-leukemia-webmd 2024-11-11T21:01:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-new-immunotherapy-for-aggressive-leukemia-webmd 2024-11-11T21:01:40+00:00 weekly 0.7 https://trial.medpath.com/news/major-immunotherapy-trial-sees-survival-benefit-in-solid-tumours 2024-11-11T20:51:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/major-immunotherapy-trial-sees-survival-benefit-in-solid-tumours 2024-11-11T20:51:28+00:00 weekly 0.7 https://trial.medpath.com/news/is-rapamycin-the-next-big-breakthrough-in-periodontitis-and-oral-cancer-treatment 2024-11-11T20:49:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/is-rapamycin-the-next-big-breakthrough-in-periodontitis-and-oral-cancer-treatment 2024-11-11T20:49:56+00:00 weekly 0.7 https://trial.medpath.com/news/perioperative-tislelizumab-with-four-cycles-of-neoadjuvant-chemotherapy-for-resectable 2024-11-11T20:32:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/perioperative-tislelizumab-with-four-cycles-of-neoadjuvant-chemotherapy-for-resectable 2024-11-11T20:32:22+00:00 weekly 0.7 https://trial.medpath.com/news/sngx-phase-3-ctcl-trial-to-initiate-before-end-of-2024-zacks-small-cap-research 2024-11-11T20:31:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sngx-phase-3-ctcl-trial-to-initiate-before-end-of-2024-zacks-small-cap-research 2024-11-11T20:31:01+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-seeks-fda-approval-of-daratumumab-for-smoldering-multiple-myeloma 2024-11-11T20:28:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-seeks-fda-approval-of-daratumumab-for-smoldering-multiple-myeloma 2024-11-11T20:28:24+00:00 weekly 0.7 https://trial.medpath.com/news/aaopt-2024-running-the-numbers-on-ophthalmic-clinical-trials-optometry-times 2024-11-11T20:23:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aaopt-2024-running-the-numbers-on-ophthalmic-clinical-trials-optometry-times 2024-11-11T20:23:49+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-squibb-s-stock-soars-after-rival-abbvie-reports-disappointing-schizophrenia-drug-trial 2024-11-11T20:16:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bristol-myers-squibb-s-stock-soars-after-rival-abbvie-reports-disappointing-schizophrenia-drug-trial 2024-11-11T20:16:43+00:00 weekly 0.7 https://trial.medpath.com/news/dosing-of-first-patient-in-a-trial-for-lsalt-peptide-is-sending-shares-higher 2024-11-11T20:07:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dosing-of-first-patient-in-a-trial-for-lsalt-peptide-is-sending-shares-higher 2024-11-11T20:07:36+00:00 weekly 0.7 https://trial.medpath.com/news/unicycive-eyes-june-fda-verdict-for-hyperphosphataemia-drug-pharmaphorum 2024-11-11T19:48:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/unicycive-eyes-june-fda-verdict-for-hyperphosphataemia-drug-pharmaphorum 2024-11-11T19:48:41+00:00 weekly 0.7 https://trial.medpath.com/news/scientists-use-microcellular-drones-to-deliver-lung-cancer-killing-drugs 2024-11-11T19:28:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scientists-use-microcellular-drones-to-deliver-lung-cancer-killing-drugs 2024-11-11T19:28:31+00:00 weekly 0.7 https://trial.medpath.com/news/largest-t-cell-clinical-trial-in-solid-tumors-explores-potential-for-precision-immunotherapy 2024-11-11T19:19:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/largest-t-cell-clinical-trial-in-solid-tumors-explores-potential-for-precision-immunotherapy 2024-11-11T19:19:53+00:00 weekly 0.7 https://trial.medpath.com/news/neurogene-reports-positive-interim-efficacy-data-from-first-four-low-dose-pediatric-participants-in-ngn-401-gene-therapy-clinical-trial-for-rett-syndrome 2024-11-11T19:11:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurogene-reports-positive-interim-efficacy-data-from-first-four-low-dose-pediatric-participants-in-ngn-401-gene-therapy-clinical-trial-for-rett-syndrome 2024-11-11T19:11:56+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-emraclidine-fails-to-reduce-schizophrenia-symptoms-compared-to-placebo 2024-11-11T18:53:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-s-emraclidine-fails-to-reduce-schizophrenia-symptoms-compared-to-placebo 2024-11-11T18:53:26+00:00 weekly 0.7 https://trial.medpath.com/news/arch-biopartners-announces-dosing-of-first-patient-in-canada-in-the-phase-ii-trial-for-stockhouse 2024-11-11T18:40:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arch-biopartners-announces-dosing-of-first-patient-in-canada-in-the-phase-ii-trial-for-stockhouse 2024-11-11T18:40:17+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-of-combined-administration-of-baekhogainsam-tang-and-low-dose-pilocarpine-on 2024-11-11T18:38:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/efficacy-of-combined-administration-of-baekhogainsam-tang-and-low-dose-pilocarpine-on 2024-11-11T18:38:03+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-drug-expected-to-rival-bristol-myers-s-new-schizophrenia-med-flunks-phase-2-test 2024-11-11T18:26:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-drug-expected-to-rival-bristol-myers-s-new-schizophrenia-med-flunks-phase-2-test 2024-11-11T18:26:58+00:00 weekly 0.7 https://trial.medpath.com/news/multifunctional-antibody-shows-promise-for-treating-several-types-of-cancer-medical-xpress 2024-11-11T18:24:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/multifunctional-antibody-shows-promise-for-treating-several-types-of-cancer-medical-xpress 2024-11-11T18:24:59+00:00 weekly 0.7 https://trial.medpath.com/news/early-serum-il-2-levels-are-associated-with-car-t-cell-expansion-post-car-t-cell-therapy 2024-11-11T18:23:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/early-serum-il-2-levels-are-associated-with-car-t-cell-expansion-post-car-t-cell-therapy 2024-11-11T18:23:53+00:00 weekly 0.7 https://trial.medpath.com/news/a-selective-bcl-2-inhibitor-with-improved-efficacy-against-known-treatment-resistant-mutants 2024-11-11T18:15:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-selective-bcl-2-inhibitor-with-improved-efficacy-against-known-treatment-resistant-mutants 2024-11-11T18:15:22+00:00 weekly 0.7 https://trial.medpath.com/news/novavax-gets-fda-approval-to-resume-testing-two-vaccines-after-clinical-hold 2024-11-11T18:00:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novavax-gets-fda-approval-to-resume-testing-two-vaccines-after-clinical-hold 2024-11-11T18:00:56+00:00 weekly 0.7 https://trial.medpath.com/news/french-biotech-company-adipopharma-secures-funding-to-initiate-clinical-trials-for-its-first 2024-11-11T17:57:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/french-biotech-company-adipopharma-secures-funding-to-initiate-clinical-trials-for-its-first 2024-11-11T17:57:01+00:00 weekly 0.7 https://trial.medpath.com/news/french-biotech-company-adipopharma-secures-funding-to-initiate-clinical-trials-for-its-first 2024-11-11T17:48:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/french-biotech-company-adipopharma-secures-funding-to-initiate-clinical-trials-for-its-first 2024-11-11T17:48:30+00:00 weekly 0.7 https://trial.medpath.com/news/french-biotech-company-adipopharma-secures-funding-to-globenewswire 2024-11-11T17:46:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/french-biotech-company-adipopharma-secures-funding-to-globenewswire 2024-11-11T17:46:58+00:00 weekly 0.7 https://trial.medpath.com/news/herbal-placebo-response-in-clinical-trials-on-irritable-bowel-syndrome-a-systematic-review 2024-11-11T17:43:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/herbal-placebo-response-in-clinical-trials-on-irritable-bowel-syndrome-a-systematic-review 2024-11-11T17:43:44+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-stock-sinks-after-schizophrenia-drug-trials-disappoint-investopedia 2024-11-11T17:38:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-stock-sinks-after-schizophrenia-drug-trials-disappoint-investopedia 2024-11-11T17:38:49+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-car-t-competitor-to-gilead-s-tecartus-biopharma-dive 2024-11-11T17:16:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-new-car-t-competitor-to-gilead-s-tecartus-biopharma-dive 2024-11-11T17:16:29+00:00 weekly 0.7 https://trial.medpath.com/news/fda-lifts-pause-on-novavax-flu-vaccine-trials-biopharma-dive 2024-11-11T17:16:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-lifts-pause-on-novavax-flu-vaccine-trials-biopharma-dive 2024-11-11T17:16:27+00:00 weekly 0.7 https://trial.medpath.com/news/theragent-and-cellvax-therapeutics-announce-first-patient-dosed-in-phase-2-trial-of-fk 2024-11-11T17:14:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/theragent-and-cellvax-therapeutics-announce-first-patient-dosed-in-phase-2-trial-of-fk 2024-11-11T17:14:04+00:00 weekly 0.7 https://trial.medpath.com/news/fda-delays-priority-review-of-neurotech-s-eye-cell-therapy-implant 2024-11-11T17:11:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-delays-priority-review-of-neurotech-s-eye-cell-therapy-implant 2024-11-11T17:11:50+00:00 weekly 0.7 https://trial.medpath.com/news/based-on-recent-fda-feedback-rapt-therapeutics-stops-zelnecirnon-program-following 2024-11-11T17:11:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/based-on-recent-fda-feedback-rapt-therapeutics-stops-zelnecirnon-program-following 2024-11-11T17:11:39+00:00 weekly 0.7 https://trial.medpath.com/news/lumateperone-demonstrates-positive-efficacy-for-schizophrenia-relapse-prevention 2024-11-11T17:11:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lumateperone-demonstrates-positive-efficacy-for-schizophrenia-relapse-prevention 2024-11-11T17:11:11+00:00 weekly 0.7 https://trial.medpath.com/news/an-overlook-of-cagrilintinide-and-semaglutide-as-it-progresses-through-phase-3-trials 2024-11-11T17:11:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/an-overlook-of-cagrilintinide-and-semaglutide-as-it-progresses-through-phase-3-trials 2024-11-11T17:11:07+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-obecabtagene-autoleucel-for-adults-with-relapsed-or-refractory-b-cell 2024-11-11T17:06:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-obecabtagene-autoleucel-for-adults-with-relapsed-or-refractory-b-cell 2024-11-11T17:06:34+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-9b-bet-collapses-as-closely-watched-schizophrenia-drug-fails-studies 2024-11-11T16:56:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-s-9b-bet-collapses-as-closely-watched-schizophrenia-drug-fails-studies 2024-11-11T16:56:58+00:00 weekly 0.7 https://trial.medpath.com/news/autolus-secures-fda-approval-for-car-t-cell-therapy-use-in-all 2024-11-11T16:56:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/autolus-secures-fda-approval-for-car-t-cell-therapy-use-in-all 2024-11-11T16:56:43+00:00 weekly 0.7 https://trial.medpath.com/news/citius-phase-1-trial-shows-27-response-rate-with-lymphir-keytruda-combo-in-cancer-study 2024-11-11T16:48:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/citius-phase-1-trial-shows-27-response-rate-with-lymphir-keytruda-combo-in-cancer-study 2024-11-11T16:48:19+00:00 weekly 0.7 https://trial.medpath.com/news/tempus-study-combined-rna-dna-testing-boosts-lung-cancer-detection-by-15-3 2024-11-11T16:48:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tempus-study-combined-rna-dna-testing-boosts-lung-cancer-detection-by-15-3 2024-11-11T16:48:19+00:00 weekly 0.7 https://trial.medpath.com/news/moleculin-biotech-advances-phase-3-trial-as-q3-shows-mixed-financial-results-mbrx-stock-news 2024-11-11T16:46:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moleculin-biotech-advances-phase-3-trial-as-q3-shows-mixed-financial-results-mbrx-stock-news 2024-11-11T16:46:37+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-provides-update-on-phase-2-results-for-emraclidine-in-schizophrenia 2024-11-11T16:46:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-provides-update-on-phase-2-results-for-emraclidine-in-schizophrenia 2024-11-11T16:46:26+00:00 weekly 0.7 https://trial.medpath.com/news/rapt-therapeutics-shares-tumble-by-48-after-zelnecirnon-programme-cull 2024-11-11T16:40:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rapt-therapeutics-shares-tumble-by-48-after-zelnecirnon-programme-cull 2024-11-11T16:40:02+00:00 weekly 0.7 https://trial.medpath.com/news/gilead-and-merck-report-successful-phase-2-results-for-investigational-once-weekly-hiv-treatment 2024-11-11T16:38:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gilead-and-merck-report-successful-phase-2-results-for-investigational-once-weekly-hiv-treatment 2024-11-11T16:38:21+00:00 weekly 0.7 https://trial.medpath.com/news/ideaya-s-ide034-breakthrough-first-in-class-cancer-drug-shows-dual-target-promise 2024-11-11T16:36:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ideaya-s-ide034-breakthrough-first-in-class-cancer-drug-shows-dual-target-promise 2024-11-11T16:36:18+00:00 weekly 0.7 https://trial.medpath.com/news/impact-of-vancomycin-therapeutic-drug-monitoring-on-mortality-in-sepsis-patients-across 2024-11-11T16:34:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/impact-of-vancomycin-therapeutic-drug-monitoring-on-mortality-in-sepsis-patients-across 2024-11-11T16:34:51+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-shares-plummet-12-as-cerevel-schizophrenia-asset-fails-phase-ii-trials 2024-11-11T16:19:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-shares-plummet-12-as-cerevel-schizophrenia-asset-fails-phase-ii-trials 2024-11-11T16:19:24+00:00 weekly 0.7 https://trial.medpath.com/news/disc-medicine-secures-200m-financing-to-support-trials 2024-11-11T16:15:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/disc-medicine-secures-200m-financing-to-support-trials 2024-11-11T16:15:52+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-squibb-s-stock-soars-after-rival-abbvie-reports-disappointing-schizophrenia-drug-trial 2024-11-11T16:11:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bristol-myers-squibb-s-stock-soars-after-rival-abbvie-reports-disappointing-schizophrenia-drug-trial 2024-11-11T16:11:57+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-stock-tumbles-on-failed-schizophrenia-drug-studies-bristol-myers-jumps 2024-11-11T16:08:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-stock-tumbles-on-failed-schizophrenia-drug-studies-bristol-myers-jumps 2024-11-11T16:08:16+00:00 weekly 0.7 https://trial.medpath.com/news/advantage-bms-as-abbvie-drug-fails-schizophrenia-trials-pharmaphorum 2024-11-11T16:06:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advantage-bms-as-abbvie-drug-fails-schizophrenia-trials-pharmaphorum 2024-11-11T16:06:54+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-survival-outcomes-in-mcspc-comparison-of-apalutamide-and-abiraterone 2024-11-11T16:06:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-survival-outcomes-in-mcspc-comparison-of-apalutamide-and-abiraterone 2024-11-11T16:06:11+00:00 weekly 0.7 https://trial.medpath.com/news/intratracheal-budesonide-mixed-with-surfactant-for-extremely-preterm-infants-jama-network 2024-11-11T16:05:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intratracheal-budesonide-mixed-with-surfactant-for-extremely-preterm-infants-jama-network 2024-11-11T16:05:44+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-sheds-38bn-in-value-after-failing-schizophrenia-drug-trials-nyse-abbv 2024-11-11T16:03:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-sheds-38bn-in-value-after-failing-schizophrenia-drug-trials-nyse-abbv 2024-11-11T16:03:27+00:00 weekly 0.7 https://trial.medpath.com/news/aaopt-2024-preserving-vision-by-detecting-and-treating-ga 2024-11-11T15:55:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aaopt-2024-preserving-vision-by-detecting-and-treating-ga 2024-11-11T15:55:01+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-tezspire-met-both-co-primary-endpoints-in-the-phase-iii-waypoint-trial-in 2024-11-11T15:53:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-tezspire-met-both-co-primary-endpoints-in-the-phase-iii-waypoint-trial-in 2024-11-11T15:53:04+00:00 weekly 0.7 https://trial.medpath.com/news/ainos-announces-irb-approval-for-sjogren-s-syndrome-clinical-study-tipranks-com 2024-11-11T15:50:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ainos-announces-irb-approval-for-sjogren-s-syndrome-clinical-study-tipranks-com 2024-11-11T15:50:57+00:00 weekly 0.7 https://trial.medpath.com/news/chimerix-announces-updated-phase-2-response-assessment-of-dordaviprone-in-ein-presswire 2024-11-11T15:43:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chimerix-announces-updated-phase-2-response-assessment-of-dordaviprone-in-ein-presswire 2024-11-11T15:43:57+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-clearance-for-phase-1-trial-of-bl-m17d1-in-solid-tumors-targeted-oncology 2024-11-11T15:41:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-clearance-for-phase-1-trial-of-bl-m17d1-in-solid-tumors-targeted-oncology 2024-11-11T15:41:10+00:00 weekly 0.7 https://trial.medpath.com/news/dana-farber-researchers-hijack-gut-bacteria-to-design-novel-form-of-cancer-immunotherapy 2024-11-11T15:39:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dana-farber-researchers-hijack-gut-bacteria-to-design-novel-form-of-cancer-immunotherapy 2024-11-11T15:39:19+00:00 weekly 0.7 https://trial.medpath.com/news/sandoz-launches-generic-paclitaxel-in-single-dose-vial-drug-store-news 2024-11-11T15:38:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sandoz-launches-generic-paclitaxel-in-single-dose-vial-drug-store-news 2024-11-11T15:38:37+00:00 weekly 0.7 https://trial.medpath.com/news/improving-precision-of-vaccine-efficacy-evaluation-using-immune-correlate-data-in-time-to 2024-11-11T15:29:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/improving-precision-of-vaccine-efficacy-evaluation-using-immune-correlate-data-in-time-to 2024-11-11T15:29:06+00:00 weekly 0.7 https://trial.medpath.com/news/theragent-and-cellvax-therapeutics-announce-first-patient-dosed-in-phase-2-trial-of-fk 2024-11-11T15:21:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/theragent-and-cellvax-therapeutics-announce-first-patient-dosed-in-phase-2-trial-of-fk 2024-11-11T15:21:41+00:00 weekly 0.7 https://trial.medpath.com/news/citius-lymphir-shows-potential-to-boost-pembrolizumab-efficacy-contract-pharma 2024-11-11T15:14:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/citius-lymphir-shows-potential-to-boost-pembrolizumab-efficacy-contract-pharma 2024-11-11T15:14:48+00:00 weekly 0.7 https://trial.medpath.com/news/parkinson-s-disease-clinical-research-in-seven-major-markets-focuses-on-disease-modifying-agents 2024-11-11T15:14:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/parkinson-s-disease-clinical-research-in-seven-major-markets-focuses-on-disease-modifying-agents 2024-11-11T15:14:16+00:00 weekly 0.7 https://trial.medpath.com/news/spravato-is-just-the-beginning-in-a-new-wave-of-depression-meds-pharmavoice 2024-11-11T15:11:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spravato-is-just-the-beginning-in-a-new-wave-of-depression-meds-pharmavoice 2024-11-11T15:11:56+00:00 weekly 0.7 https://trial.medpath.com/news/trial-shows-acupuncture-is-feasible-for-reducing-pain-in-the-emergency-department 2024-11-11T15:03:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trial-shows-acupuncture-is-feasible-for-reducing-pain-in-the-emergency-department 2024-11-11T15:03:37+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-tumbles-after-new-schizophrenia-drug-fails-two-trials-yahoo-finance 2024-11-11T15:03:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-tumbles-after-new-schizophrenia-drug-fails-two-trials-yahoo-finance 2024-11-11T15:03:23+00:00 weekly 0.7 https://trial.medpath.com/news/glp-1-and-sglt2-drugs-may-help-prevent-second-strokes-and-heart-attacks-in-stroke-survivors 2024-11-11T15:02:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glp-1-and-sglt2-drugs-may-help-prevent-second-strokes-and-heart-attacks-in-stroke-survivors 2024-11-11T15:02:26+00:00 weekly 0.7 https://trial.medpath.com/news/innovative-approaches-to-gynecologic-cancer-prognosis-fueled-by-metabolomics 2024-11-11T15:01:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innovative-approaches-to-gynecologic-cancer-prognosis-fueled-by-metabolomics 2024-11-11T15:01:03+00:00 weekly 0.7 https://trial.medpath.com/news/uk-mhra-at-least-half-of-novel-drug-filings-to-take-national-assessment-route 2024-11-11T14:46:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-mhra-at-least-half-of-novel-drug-filings-to-take-national-assessment-route 2024-11-11T14:46:09+00:00 weekly 0.7 https://trial.medpath.com/news/citius-lymphir-shows-potential-to-boost-pembrolizumab-efficacy-contract-pharma 2024-11-11T14:39:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/citius-lymphir-shows-potential-to-boost-pembrolizumab-efficacy-contract-pharma 2024-11-11T14:39:59+00:00 weekly 0.7 https://trial.medpath.com/news/emraclidine-for-schizophrenia-fails-to-meet-primary-endpoints-in-phase-2-empower-trials 2024-11-11T14:39:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/emraclidine-for-schizophrenia-fails-to-meet-primary-endpoints-in-phase-2-empower-trials 2024-11-11T14:39:09+00:00 weekly 0.7 https://trial.medpath.com/news/rapt-crashes-after-axing-atopic-dermatitis-asthma-hopeful-cites-liver-injury-biospace 2024-11-11T14:34:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rapt-crashes-after-axing-atopic-dermatitis-asthma-hopeful-cites-liver-injury-biospace 2024-11-11T14:34:50+00:00 weekly 0.7 https://trial.medpath.com/news/ema-benefits-from-astrazeneca-significantly-outweigh-side-effects-telegraph-telegraph 2024-11-11T14:34:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-benefits-from-astrazeneca-significantly-outweigh-side-effects-telegraph-telegraph 2024-11-11T14:34:36+00:00 weekly 0.7 https://trial.medpath.com/news/viiv-healthcare-announces-data-demonstrating-dovato-dtg-3tc-is-highly-effective-in 2024-11-11T14:31:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/viiv-healthcare-announces-data-demonstrating-dovato-dtg-3tc-is-highly-effective-in 2024-11-11T14:31:35+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-rockets-12-after-abbvie-s-schizophrenia-drug-fails 2024-11-11T14:27:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bristol-myers-rockets-12-after-abbvie-s-schizophrenia-drug-fails 2024-11-11T14:27:52+00:00 weekly 0.7 https://trial.medpath.com/news/schizophrenia-drug-abbvie-picked-up-in-9-billion-acquisition-fails-in-key-trials-stat-news 2024-11-11T14:26:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/schizophrenia-drug-abbvie-picked-up-in-9-billion-acquisition-fails-in-key-trials-stat-news 2024-11-11T14:26:47+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-shares-slip-after-schizophrenia-drug-trial-misses-primary-endpoint-yahoo-finance 2024-11-11T14:20:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-shares-slip-after-schizophrenia-drug-trial-misses-primary-endpoint-yahoo-finance 2024-11-11T14:20:12+00:00 weekly 0.7 https://trial.medpath.com/news/review-of-fda-approved-jak-inhibitors-for-alopecia-areata-hcplive 2024-11-11T14:08:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/review-of-fda-approved-jak-inhibitors-for-alopecia-areata-hcplive 2024-11-11T14:08:57+00:00 weekly 0.7 https://trial.medpath.com/news/how-pharmacists-can-make-an-impact-when-treating-dedifferentiated-liposarcoma-with 2024-11-11T14:06:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-pharmacists-can-make-an-impact-when-treating-dedifferentiated-liposarcoma-with 2024-11-11T14:06:08+00:00 weekly 0.7 https://trial.medpath.com/news/iterum-s-sulopenem-receives-fda-approval-for-treatment-of-uncomplicated-urinary-tract-infections 2024-11-11T14:03:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iterum-s-sulopenem-receives-fda-approval-for-treatment-of-uncomplicated-urinary-tract-infections 2024-11-11T14:03:53+00:00 weekly 0.7 https://trial.medpath.com/news/fda-receives-application-seeking-approval-of-darzalex-faspro-in-smoldering-myeloma 2024-11-11T14:02:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-receives-application-seeking-approval-of-darzalex-faspro-in-smoldering-myeloma 2024-11-11T14:02:17+00:00 weekly 0.7 https://trial.medpath.com/news/resq-pharma-receives-pdufa-date-for-lipidrescuetm-as-a-potential-first-ever-fda 2024-11-11T13:57:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/resq-pharma-receives-pdufa-date-for-lipidrescuetm-as-a-potential-first-ever-fda 2024-11-11T13:57:02+00:00 weekly 0.7 https://trial.medpath.com/news/citius-pharmaceuticals-inc-and-citius-oncology-inc-announce-promising-pr-newswire 2024-11-11T13:50:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/citius-pharmaceuticals-inc-and-citius-oncology-inc-announce-promising-pr-newswire 2024-11-11T13:50:47+00:00 weekly 0.7 https://trial.medpath.com/news/inflammatix-initiates-triveritytm-for-improved-management-of-emergency-department 2024-11-11T13:48:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inflammatix-initiates-triveritytm-for-improved-management-of-emergency-department 2024-11-11T13:48:52+00:00 weekly 0.7 https://trial.medpath.com/news/tempus-publishes-study-highlighting-benefits-of-concurrent-rna-and-dna-sequencing-in 2024-11-11T13:47:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tempus-publishes-study-highlighting-benefits-of-concurrent-rna-and-dna-sequencing-in 2024-11-11T13:47:41+00:00 weekly 0.7 https://trial.medpath.com/news/your-health-blood-test-breakthrough-revolutionizing-postpartum-depression-wafb 2024-11-11T13:41:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/your-health-blood-test-breakthrough-revolutionizing-postpartum-depression-wafb 2024-11-11T13:41:12+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-fda-removes-clinical-hold-on-novavax-s-covid-19-influenza-combination-and-stand 2024-11-11T13:38:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-s-fda-removes-clinical-hold-on-novavax-s-covid-19-influenza-combination-and-stand 2024-11-11T13:38:42+00:00 weekly 0.7 https://trial.medpath.com/news/tivozanib-monotherapy-outperforms-combination-therapy-in-post-ici-rcc-nature 2024-11-11T13:35:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tivozanib-monotherapy-outperforms-combination-therapy-in-post-ici-rcc-nature 2024-11-11T13:35:30+00:00 weekly 0.7 https://trial.medpath.com/news/intellia-therapeutics-q3-earnings-report-puts-phase-ii-results-in-focus-nasdaq-ntla 2024-11-11T13:34:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intellia-therapeutics-q3-earnings-report-puts-phase-ii-results-in-focus-nasdaq-ntla 2024-11-11T13:34:50+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-fda-removes-clinical-hold-on-novavax-s-covid-19-influenza-combination-and-stand 2024-11-11T13:32:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-s-fda-removes-clinical-hold-on-novavax-s-covid-19-influenza-combination-and-stand 2024-11-11T13:32:39+00:00 weekly 0.7 https://trial.medpath.com/news/unicycive-says-fda-accepts-nda-for-oxylanthanum-carbonate-to-treat-patients-with-ckd 2024-11-11T13:32:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/unicycive-says-fda-accepts-nda-for-oxylanthanum-carbonate-to-treat-patients-with-ckd 2024-11-11T13:32:28+00:00 weekly 0.7 https://trial.medpath.com/news/kills-ovarian-cancer-without-toxicity-in-key-study-cero-stock-news 2024-11-11T13:22:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kills-ovarian-cancer-without-toxicity-in-key-study-cero-stock-news 2024-11-11T13:22:59+00:00 weekly 0.7 https://trial.medpath.com/news/rapt-therapeutics-halts-key-drug-program-after-fda-safety-concerns-liver-injury 2024-11-11T13:19:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rapt-therapeutics-halts-key-drug-program-after-fda-safety-concerns-liver-injury 2024-11-11T13:19:03+00:00 weekly 0.7 https://trial.medpath.com/news/first-in-class-bispecific-antibody-alg-apv-527-meets-important-trial-endpoints-in-phase-1 2024-11-11T13:18:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-in-class-bispecific-antibody-alg-apv-527-meets-important-trial-endpoints-in-phase-1 2024-11-11T13:18:58+00:00 weekly 0.7 https://trial.medpath.com/news/cg-oncology-announces-nature-medicine-publication-of-phase-globenewswire 2024-11-11T13:15:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cg-oncology-announces-nature-medicine-publication-of-phase-globenewswire 2024-11-11T13:15:59+00:00 weekly 0.7 https://trial.medpath.com/news/annovis-bio-reports-third-quarter-financial-results-and-provides-business-update 2024-11-11T13:15:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/annovis-bio-reports-third-quarter-financial-results-and-provides-business-update 2024-11-11T13:15:54+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-amgen-s-tezspire-shows-promise-in-phase-3-crswnp-trial-pmlive 2024-11-11T13:15:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-amgen-s-tezspire-shows-promise-in-phase-3-crswnp-trial-pmlive 2024-11-11T13:15:53+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-autolus-aucatzyl-to-treat-acute-lymphoblastic-leukaemia-pmlive 2024-11-11T13:15:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-autolus-aucatzyl-to-treat-acute-lymphoblastic-leukaemia-pmlive 2024-11-11T13:15:49+00:00 weekly 0.7 https://trial.medpath.com/news/scottish-medicines-consortium-approves-car-t-cell-therapy-for-blood-cancer 2024-11-11T13:14:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scottish-medicines-consortium-approves-car-t-cell-therapy-for-blood-cancer 2024-11-11T13:14:06+00:00 weekly 0.7 https://trial.medpath.com/news/improving-alzheimer-diagnosis-with-innovative-blood-based-biomarker-tests-and-bd-tau 2024-11-11T13:13:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/improving-alzheimer-diagnosis-with-innovative-blood-based-biomarker-tests-and-bd-tau 2024-11-11T13:13:16+00:00 weekly 0.7 https://trial.medpath.com/news/nammi-therapeutics-doses-first-subject-in-trial-of-qxl138am-for-multiple-myeloma 2024-11-11T13:11:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nammi-therapeutics-doses-first-subject-in-trial-of-qxl138am-for-multiple-myeloma 2024-11-11T13:11:56+00:00 weekly 0.7 https://trial.medpath.com/news/ainos-announces-irb-approval-for-sjogren-s-syndrome-clinical-study-at-shuang-ho 2024-11-11T13:11:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ainos-announces-irb-approval-for-sjogren-s-syndrome-clinical-study-at-shuang-ho 2024-11-11T13:11:49+00:00 weekly 0.7 https://trial.medpath.com/news/aethlon-medical-reaches-key-milestone-with-enrollment-of-the-first-patient-in-fpi-markets-data 2024-11-11T13:10:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aethlon-medical-reaches-key-milestone-with-enrollment-of-the-first-patient-in-fpi-markets-data 2024-11-11T13:10:16+00:00 weekly 0.7 https://trial.medpath.com/news/phase-1-study-of-isatuximab-monotherapy-in-chinese-patients-with-relapsed-refractory 2024-11-11T13:08:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-1-study-of-isatuximab-monotherapy-in-chinese-patients-with-relapsed-refractory 2024-11-11T13:08:01+00:00 weekly 0.7 https://trial.medpath.com/news/ainos-advances-sjogren-s-treatment-key-trial-for-veldona-r-gets-irb-green-light 2024-11-11T13:05:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ainos-advances-sjogren-s-treatment-key-trial-for-veldona-r-gets-irb-green-light 2024-11-11T13:05:24+00:00 weekly 0.7 https://trial.medpath.com/news/annovis-bio-gets-fda-nod-for-phase-3-alzheimer-s-trial-cuts-losses-40-in-q3-anvs-stock-news 2024-11-11T13:05:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/annovis-bio-gets-fda-nod-for-phase-3-alzheimer-s-trial-cuts-losses-40-in-q3-anvs-stock-news 2024-11-11T13:05:22+00:00 weekly 0.7 https://trial.medpath.com/news/can-fite-achieves-milestone-with-first-patient-dosing-in-pancreatic-cancer-phase-iia-clinical-trial 2024-11-11T13:02:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/can-fite-achieves-milestone-with-first-patient-dosing-in-pancreatic-cancer-phase-iia-clinical-trial 2024-11-11T13:02:53+00:00 weekly 0.7 https://trial.medpath.com/news/chimerix-announces-updated-phase-2-response-assessment-of-dordaviprone-in-morningstar 2024-11-11T13:02:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chimerix-announces-updated-phase-2-response-assessment-of-dordaviprone-in-morningstar 2024-11-11T13:02:53+00:00 weekly 0.7 https://trial.medpath.com/news/boston-scientific-resumes-enrolment-in-pulsed-field-ablation-trial-clinical-trials-arena 2024-11-11T13:02:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boston-scientific-resumes-enrolment-in-pulsed-field-ablation-trial-clinical-trials-arena 2024-11-11T13:02:48+00:00 weekly 0.7 https://trial.medpath.com/news/groundbreaking-research-finds-that-alzheimer-s-can-be-transmitted-between-people 2024-11-11T12:49:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/groundbreaking-research-finds-that-alzheimer-s-can-be-transmitted-between-people 2024-11-11T12:49:43+00:00 weekly 0.7 https://trial.medpath.com/news/alembic-receives-usfda-final-approval-for-diltiazem-hydrochloride-er-capsules 2024-11-11T12:48:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alembic-receives-usfda-final-approval-for-diltiazem-hydrochloride-er-capsules 2024-11-11T12:48:34+00:00 weekly 0.7 https://trial.medpath.com/news/cytokinetics-announces-initiation-of-phase-1-clinical-study-of-ck-4015089-yahoo-finance 2024-11-11T12:39:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytokinetics-announces-initiation-of-phase-1-clinical-study-of-ck-4015089-yahoo-finance 2024-11-11T12:39:55+00:00 weekly 0.7 https://trial.medpath.com/news/moleculin-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-11T12:39:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moleculin-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-11T12:39:14+00:00 weekly 0.7 https://trial.medpath.com/news/arch-biopartners-announces-dosing-of-first-patient-in-canada-in-the-phase-ii-trial-for 2024-11-11T12:35:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arch-biopartners-announces-dosing-of-first-patient-in-canada-in-the-phase-ii-trial-for 2024-11-11T12:35:17+00:00 weekly 0.7 https://trial.medpath.com/news/cytokinetics-announces-initiation-of-phase-1-clinical-study-of-ck-4015089-stock-titan 2024-11-11T12:34:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytokinetics-announces-initiation-of-phase-1-clinical-study-of-ck-4015089-stock-titan 2024-11-11T12:34:55+00:00 weekly 0.7 https://trial.medpath.com/news/arch-biopartners-announces-dosing-of-first-patient-in-globenewswire 2024-11-11T12:32:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arch-biopartners-announces-dosing-of-first-patient-in-globenewswire 2024-11-11T12:32:13+00:00 weekly 0.7 https://trial.medpath.com/news/can-fite-achieves-milestone-with-first-patient-dosing-in-pancreatic-cancer-phase-iia-clinical-trial 2024-11-11T12:26:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/can-fite-achieves-milestone-with-first-patient-dosing-in-pancreatic-cancer-phase-iia-clinical-trial 2024-11-11T12:26:41+00:00 weekly 0.7 https://trial.medpath.com/news/gastric-cancer-awareness-month-2024-looking-back-at-progress-for-cell-therapy-cgtlive-r 2024-11-11T12:20:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gastric-cancer-awareness-month-2024-looking-back-at-progress-for-cell-therapy-cgtlive-r 2024-11-11T12:20:08+00:00 weekly 0.7 https://trial.medpath.com/news/ethics-approval-received-in-indonesia-to-commence-dosing-in-a-registrational-phase-3 2024-11-11T12:18:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ethics-approval-received-in-indonesia-to-commence-dosing-in-a-registrational-phase-3 2024-11-11T12:18:31+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-amgen-claim-late-stage-win-in-chronic-rhinosinusitis-but-analyst-flags 2024-11-11T12:17:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-amgen-claim-late-stage-win-in-chronic-rhinosinusitis-but-analyst-flags 2024-11-11T12:17:08+00:00 weekly 0.7 https://trial.medpath.com/news/can-fite-launches-phase-iia-trial-for-fda-designated-orphan-drug-in-pancreatic-cancer 2024-11-11T12:06:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/can-fite-launches-phase-iia-trial-for-fda-designated-orphan-drug-in-pancreatic-cancer 2024-11-11T12:06:48+00:00 weekly 0.7 https://trial.medpath.com/news/chimerix-cancer-drug-shows-28-response-rate-in-phase-2-brain-tumor-trial-cmrx-stock-news 2024-11-11T12:06:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chimerix-cancer-drug-shows-28-response-rate-in-phase-2-brain-tumor-trial-cmrx-stock-news 2024-11-11T12:06:47+00:00 weekly 0.7 https://trial.medpath.com/news/springworks-therapeutics-announces-mirdametinib-data-to-be-presented-at-the-2024-stock-titan 2024-11-11T12:06:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/springworks-therapeutics-announces-mirdametinib-data-to-be-presented-at-the-2024-stock-titan 2024-11-11T12:06:47+00:00 weekly 0.7 https://trial.medpath.com/news/moleculin-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-11T12:06:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moleculin-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-11T12:06:46+00:00 weekly 0.7 https://trial.medpath.com/news/momentis-surgical-receives-fda-510-k-clearance-for-second-generation-anovo-r-robotic 2024-11-11T12:05:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/momentis-surgical-receives-fda-510-k-clearance-for-second-generation-anovo-r-robotic 2024-11-11T12:05:52+00:00 weekly 0.7 https://trial.medpath.com/news/unicycive-therapeutics-announces-u-s-fda-acceptance-of-the-globenewswire 2024-11-11T12:04:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/unicycive-therapeutics-announces-u-s-fda-acceptance-of-the-globenewswire 2024-11-11T12:04:30+00:00 weekly 0.7 https://trial.medpath.com/news/can-fite-achieves-milestone-with-first-patient-dosing-in-pancreatic-cancer-phase-iia-clinical-trial 2024-11-11T12:04:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/can-fite-achieves-milestone-with-first-patient-dosing-in-pancreatic-cancer-phase-iia-clinical-trial 2024-11-11T12:04:28+00:00 weekly 0.7 https://trial.medpath.com/news/unicycive-s-kidney-disease-drug-gets-fda-review-date-aims-for-2025-launch-uncy-stock-news 2024-11-11T12:02:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/unicycive-s-kidney-disease-drug-gets-fda-review-date-aims-for-2025-launch-uncy-stock-news 2024-11-11T12:02:45+00:00 weekly 0.7 https://trial.medpath.com/news/australian-german-research-finds-world-first-cure-for-deadly-skin-disease-daijiworld-com 2024-11-11T11:38:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/australian-german-research-finds-world-first-cure-for-deadly-skin-disease-daijiworld-com 2024-11-11T11:38:36+00:00 weekly 0.7 https://trial.medpath.com/news/paratek-s-antibiotic-succeeds-in-phase-iib-lung-disease-trial 2024-11-11T11:35:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/paratek-s-antibiotic-succeeds-in-phase-iib-lung-disease-trial 2024-11-11T11:35:03+00:00 weekly 0.7 https://trial.medpath.com/news/springworks-therapeutics-announces-publication-of-the-pivotal-phase-2b-reneu-trial 2024-11-11T11:33:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/springworks-therapeutics-announces-publication-of-the-pivotal-phase-2b-reneu-trial 2024-11-11T11:33:23+00:00 weekly 0.7 https://trial.medpath.com/news/ideaya-announces-development-candidate-nomination-of-ide034-a-potential-first-in 2024-11-11T11:31:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ideaya-announces-development-candidate-nomination-of-ide034-a-potential-first-in 2024-11-11T11:31:44+00:00 weekly 0.7 https://trial.medpath.com/news/alembic-pharmaceuticals-gains-us-fda-approval-for-diltiazem-capsules-to-treat-hypertension 2024-11-11T11:31:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alembic-pharmaceuticals-gains-us-fda-approval-for-diltiazem-capsules-to-treat-hypertension 2024-11-11T11:31:31+00:00 weekly 0.7 https://trial.medpath.com/news/biocytogen-announces-ideaya-s-nomination-of-development-candidate-ide034-a-via-ritzau 2024-11-11T11:22:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biocytogen-announces-ideaya-s-nomination-of-development-candidate-ide034-a-via-ritzau 2024-11-11T11:22:43+00:00 weekly 0.7 https://trial.medpath.com/news/ema-grants-limited-market-designation-to-vivesto-s-paccal-vet-marketscreener 2024-11-11T11:20:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-grants-limited-market-designation-to-vivesto-s-paccal-vet-marketscreener 2024-11-11T11:20:37+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-bags-health-canada-nod-for-rsv-vaccine-for-adults-aged-60-years-and-older 2024-11-11T11:14:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moderna-bags-health-canada-nod-for-rsv-vaccine-for-adults-aged-60-years-and-older 2024-11-11T11:14:48+00:00 weekly 0.7 https://trial.medpath.com/news/patient-with-sickle-cell-disease-dies-from-complications-related-to-busulfan-conditioning 2024-11-11T11:09:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patient-with-sickle-cell-disease-dies-from-complications-related-to-busulfan-conditioning 2024-11-11T11:09:53+00:00 weekly 0.7 https://trial.medpath.com/news/weight-loss-meds-help-stroke-survivors-prevent-stroke-recurrence-death 2024-11-11T11:06:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/weight-loss-meds-help-stroke-survivors-prevent-stroke-recurrence-death 2024-11-11T11:06:57+00:00 weekly 0.7 https://trial.medpath.com/news/hourglass-shaped-stent-might-ease-tough-to-treat-angina 2024-11-11T11:04:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hourglass-shaped-stent-might-ease-tough-to-treat-angina 2024-11-11T11:04:32+00:00 weekly 0.7 https://trial.medpath.com/news/trbc1-car-t-cell-therapy-in-peripheral-t-cell-lymphoma-a-phase-1-2-trial-nature 2024-11-11T10:58:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trbc1-car-t-cell-therapy-in-peripheral-t-cell-lymphoma-a-phase-1-2-trial-nature 2024-11-11T10:58:32+00:00 weekly 0.7 https://trial.medpath.com/news/vivesto-s-paccal-vet-receives-limited-market-classification-in-eu-tradingview-news 2024-11-11T10:51:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vivesto-s-paccal-vet-receives-limited-market-classification-in-eu-tradingview-news 2024-11-11T10:51:24+00:00 weekly 0.7 https://trial.medpath.com/news/alembic-pharma-receives-usfda-approval-for-hypertension-drug-equitypandit 2024-11-11T10:47:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alembic-pharma-receives-usfda-approval-for-hypertension-drug-equitypandit 2024-11-11T10:47:15+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-s-mresvia-vaccine-gains-health-canada-approval-pharmaceutical-technology 2024-11-11T10:46:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moderna-s-mresvia-vaccine-gains-health-canada-approval-pharmaceutical-technology 2024-11-11T10:46:45+00:00 weekly 0.7 https://trial.medpath.com/news/syncona-s-autolus-wins-fda-approval-for-aggressive-leukaemia-therapy-marketscreener 2024-11-11T10:38:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syncona-s-autolus-wins-fda-approval-for-aggressive-leukaemia-therapy-marketscreener 2024-11-11T10:38:28+00:00 weekly 0.7